

=> d his

(FILE 'HOME' ENTERED AT 16:20:37 ON 14 APR 2004)

FILE 'MEDLINE, CAPLUS, SCISEARCH, BIOSIS, USPATFULL, PCTFULL' ENTERED AT
16:21:21 ON 14 APR 2004

L1 364 S GASTRIN(S)DIABETES
L2 584 S EGF(S)DIABETES
L3 268 S (ADMINISTER? OR TREAT OR TREATMENT) (S) (L1 OR L2)
L4 32 S L1(S)L2
L5 257 DUP REM L3 (11 DUPLICATES REMOVED)
L6 22 DUP REM L4 (10 DUPLICATES REMOVED)
L7 13 S GASTRIN(S) (LEU OR LEUCINE) (S) ((POSITION? OR RESIDUE OR ACID) (
L8 12 DUP REM L7 (1 DUPLICATE REMOVED)
L9 67 S EGF(S) ((DELET?(3W) (C(W) (TERMINUS OR TERMINAL))) OR (NEUTRAL(S
L10 53 DUP REM L9 (14 DUPLICATES REMOVED)
L11 2 S L10 AND L2
L12 6 S L1 AND L7
L13 27 S (ADMINISTER? OR TREAT OR TREATMENT) (S) (L8 OR L10)
L14 27 S (ADMINISTER? OR TREAT OR TREATMENT) (S) (L7 OR L9)
L15 27 DUP REM L14 (0 DUPLICATES REMOVED)
L16 16 S L5 AND L6
L17 83 S EGF(S) (DELETE OR DELETION) (S) (TWO OR 2) (S) (C(W) (TERMINUS OR T
L18 33 S EGF(S) (DELETE OR DELETION) (3W) (TWO OR 2) (S) (C(W) (TERMINUS OR
L19 33 DUP REM L18 (0 DUPLICATES REMOVED)
L20 19 S (ADMINISTER? OR TREAT OR TREATMENT) (S) L19

L Number	Hits	Search Text	DB	Time stamp
1	56	(gastrin near3 cck) near3 ligand\$	USPAT; US-PGPUB; EPO; DERWENT	2004/04/14 15:24
2	390	egf adj3 ligand\$	USPAT; US-PGPUB; EPO; DERWENT	2004/04/14 15:25
3	13	((gastrin near3 cck) near3 ligand\$) with (egf adj3 ligand\$)	USPAT; US-PGPUB; EPO; DERWENT	2004/04/14 15:59
4	13	(gastrin with egf) same diabetes	USPAT; US-PGPUB; EPO; DERWENT	2004/04/14 15:59

=> d his

(FILE 'HOME' ENTERED AT 16:20:37 ON 14 APR 2004)

FILE 'MEDLINE, CAPLUS, SCISEARCH, BIOSIS, USPATFULL, PCTFULL' ENTERED AT
16:21:21 ON 14 APR 2004

L1 364 S GASTRIN(S)DIABETES
L2 584 S EGF(S)DIABETES
L3 268 S (ADMINISTER? OR TREAT OR TREATMENT) (S) (L1 OR L2)
L4 32 S L1(S)L2
L5 257 DUP REM L3 (11 DUPLICATES REMOVED)
L6 22 DUP REM L4 (10 DUPLICATES REMOVED)

=> s gastrin(s)(leu or leucine)(s)((position? or residue or acid)(w)15)

L7 13 GASTRIN(S)(LEU OR LEUCINE)(S)((POSITION? OR RESIDUE OR ACID)(W)
15)

=> dup rem l7

PROCESSING COMPLETED FOR L7

L8 12 DUP REM L7 (1 DUPLICATE REMOVED)

=> s egf(s)((delet?(3w)(c(w)(terminus or terminal)) or (neutral(s)amino(s)acid(s)51))
UNMATCHED LEFT PARENTHESIS 'S)((DELET?'

The number of right parentheses in a query must be equal to the
number of left parentheses.

=> s egf(s)((delet?(3w)(c(w)(terminus or terminal))) or (neutral(s)amino(s)acid(s)51))

L9 67 EGF(S)((DELET?(3W)(C(W)(TERMINUS OR TERMINAL))) OR (NEUTRAL(S)
AMINO(S) ACID(S) 51))

=> dup rem l9

PROCESSING COMPLETED FOR L9

L10 53 DUP REM L9 (14 DUPLICATES REMOVED)

=> d his

(FILE 'HOME' ENTERED AT 16:20:37 ON 14 APR 2004)

FILE 'MEDLINE, CAPLUS, SCISEARCH, BIOSIS, USPATFULL, PCTFULL' ENTERED AT
16:21:21 ON 14 APR 2004

L1 364 S GASTRIN(S)DIABETES
L2 584 S EGF(S)DIABETES
L3 268 S (ADMINISTER? OR TREAT OR TREATMENT) (S) (L1 OR L2)
L4 32 S L1(S)L2
L5 257 DUP REM L3 (11 DUPLICATES REMOVED)
L6 22 DUP REM L4 (10 DUPLICATES REMOVED)
L7 13 S GASTRIN(S)(LEU OR LEUCINE)(S)((POSITION? OR RESIDUE OR ACID) (
L8 12 DUP REM L7 (1 DUPLICATE REMOVED)
L9 67 S EGF(S)((DELET?(3W)(C(W)(TERMINUS OR TERMINAL))) OR (NEUTRAL(S)
L10 53 DUP REM L9 (14 DUPLICATES REMOVED)

=> s l10 and l2

L11 2 L10 AND L2

=> d ibib abs 1-2

L11 ANSWER 1 OF 2 USPATFULL on STN

ACCESSION NUMBER: 2002:185270 USPATFULL

TITLE: Prolonged efficacy of islet neogenesis therapy methods
with a gastrin/CCK receptor ligand and an **EGF**

receptor ligand composition in subjects with
preexisting **diabetes**
INVENTOR(S): Brand, Stephen J., Lincoln, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002098178	A1	20020725
APPLICATION INFO.:	US 2002-44048	A1	20020111 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-261638P	20010112 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Sonia K. Guterman, Esq., Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C, One Financial Center, Boston, MA, 02111	
NUMBER OF CLAIMS:	68	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Page(s)	
LINE COUNT:	1032	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods are provided for achieving in vivo islet cell regeneration in subjects with preexisting **diabetes**. The methods comprise short term treatment with a composition having a gastrin/cholecystokinin receptor ligand and an **EGF** receptor ligand. Treatment with such a composition for a short term resulted in a prolonged period of increased insulin release, decreased fasting blood glucose, and improved glucose tolerance, the prolonged efficacy, the period being considered from the time of cessation of treatment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 2 OF 2 PCTFULL COPYRIGHT 2004 Univentio on STN
ACCESSION NUMBER: 2002055152 PCTFULL ED 20020725 EW 200229
TITLE (ENGLISH): PROLONGED EFFICACY OF ISLET NEOGENESIS THERAPY METHODS
WITH A GASTRIN/CCK RECEPTOR LIGAND AND AN **EGF**
RECEPTOR LIGAND COMPOSITION IN SUBJECTS WITH
PREEXISTING **DIABETES**
TITLE (FRENCH): EFFICACITE PROLONGEE DE METHODES DE SOINS DE NEOGENESE
D'ILOT AVEC UNE COMPOSITION DE LIGAND DE RECEPTEUR DE
GASTRINE/CCK ET DE LIGAND DE RECEPTEUR D'**EGF**
CHEZ DES SUJETS A **DIABETES** PREEXISTANTS
INVENTOR(S): BRAND, Stephen, J., 161 Bedford Road, Lincoln, MA
01773, US
PATENT ASSIGNEE(S): WARATAH PHARMACEUTICALS, INC., 1000 Roessler Road,
Suite N, Woburn, MA 01801, US [US, CA]
AGENT: GUTERMAN, Sonia, K.\$, Mintz, Levin, Cohn, Ferris,
Glovsky and Popeo, P.C., One Financial Center, Boston,
MA 02111\$, US
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
DESIGNATED STATES	WO 2002055152	A2	20020718
W:	AU CA JP		
RW (EPO):	AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE		

TR
APPLICATION INFO.: WO 2002-US685 A 20020111
PRIORITY INFO.: US 2001-60/261,638 20010112
ABEN Compositions and methods are provided for achieving in vivo islet cell regeneration in subjects with preexisting **diabetes**. The methods comprise short term treatment with a composition having a gastrin/cholecystokinin receptor ligand and an **EGF** receptor ligand. Treatment with such a composition for a short term resulted in a prolonged period of increased insulin release, decreased fasting blood glucose, and improved glucose tolerance, the prolonged efficacy, the period being considered from the time of cessation of treatment.
ABFR L'invention concerne des compositions et des methodes permettant de realiser une regeneration cellulaire d'ilot <i>in vivo</i> chez des sujets a **diabetes** preexistants. Les methodes consistent en un traitement court terme avec une composition contenant un ligand de recepteur de gastrine/CCK (cholecystokinine) et un ligand de recepteur d'**EGF** (facteur de croissance epidermique). Un traitement court terme avec une telle composition resulte en une periode prolongee de liberation amelioree d'insuline, de diminution de la glycemie a jeun, et de tolerance au glucose amelioree, la duree de l'efficacite prolongee etant comptee a partir de la cessation du traitement.

=> d his

(FILE 'HOME' ENTERED AT 16:20:37 ON 14 APR 2004)

FILE 'MEDLINE, CAPLUS, SCISEARCH, BIOSIS, USPATFULL, PCTFULL' ENTERED AT 16:21:21 ON 14 APR 2004

L1 364 S GASTRIN(S)DIABETES
L2 584 S EGF(S)DIABETES
L3 268 S (ADMINISTER? OR TREAT OR TREATMENT) (S) (L1 OR L2)
L4 32 S L1(S)L2
L5 257 DUP REM L3 (11 DUPLICATES REMOVED)
L6 22 DUP REM L4 (10 DUPLICATES REMOVED)
L7 13 S GASTRIN(S) (LEU OR LEUCINE) (S) ((POSITION? OR RESIDUE OR ACID) (
L8 12 DUP REM L7 (1 DUPLICATE REMOVED)
L9 67 S EGF(S) ((DELET?(3W) (C(W) (TERMINUS OR TERMINAL))) OR (NEUTRAL(S
L10 53 DUP REM L9 (14 DUPLICATES REMOVED)
L11 2 S L10 AND L2

=> s l1 and l7

L12 6 L1 AND L7

=> d ibib abs 1-6

L12 ANSWER 1 OF 6 USPATFULL on STN

ACCESSION NUMBER: 2004:50392 USPATFULL
TITLE: Treatment for diabetes
INVENTOR(S): Brand, Stephen J., Lincoln, MA, UNITED STATES
Cruz, Antonio, Toronto, CANADA
Rabinovitch, Alex, Edmonton, CANADA
Suarez-Pinzon, Wilma Lucia, Edmonton, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004037818	A1	20040226
APPLICATION INFO.:	US 2003-446612	A1	20030527 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-29551, filed on 20 Dec 2001, PENDING Continuation of Ser. No. US		

1999-241100, filed on 29 Jan 1999, GRANTED, Pat. No. US
 6558952 Continuation-in-part of Ser. No. US
 1998-127028, filed on 30 Jul 1998, GRANTED, Pat. No. US
 6288301

	NUMBER	DATE
--	--------	------

PRIORITY INFORMATION:	US 2002-384357P	20020530 (60)
	US 2002-382921P	20020524 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: RAE-VENTER LAW GROUP, P.C., P.O. BOX 1898, MONTEREY,
CA, 93942-1898

NUMBER OF CLAIMS: 20

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 16 Drawing Page(s)

LINE COUNT: 1522

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Proliferating pancreatic islet cells obtained by the method of isolating a population of cells that preferably includes predominantly islet precursor cells that express one or more marker associated with an islet precursor cell and providing the precursor cells with one or more a pancreatic differentiation agent so that a population of cells is obtained that has a high proportion of cells with phenotypic characteristics of functional pancreatic islet β -cells. Optionally, the precursor cells are pretreated by providing them with one or more cell expansion agent to increase the number of cells in the population prior to differentiation. The pancreatic differentiation agent composition comprises a gastrin/CCK receptor ligand, e.g., a gastrin, in an amount sufficient to effect differentiation of pancreatic islet precursor cells to mature insulin-secreting cells. The cell expansion agent composition comprises one or more epidermal growth factor (EGF) receptor ligand in an amount sufficient to stimulate proliferation of the precursor cells. The methods of treatment include transplanting either undifferentiated precursor cells and providing the pancreatic differentiation agent either alone or in combination with the cell expansion agent in situ, or transplanting the functional pancreatic islet β -cells into the patient. The pancreatic islet β -cells can be used for drug screening, and replenishing pancreatic function in the context of clinical treatment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 2 OF 6 USPATFULL on STN

ACCESSION NUMBER: 2004:31743 USPATFULL

TITLE: Compositions and methods for treating diabetes

INVENTOR(S): Brand, Stephen J., Lincoln, MA, UNITED STATES
Cruz, Antonio, Toronto, CANADA

	NUMBER	KIND	DATE
--	--------	------	------

PATENT INFORMATION:	US 2004023885	A1	20040205
APPLICATION INFO.:	US 2003-457126	A1	20030609 (10)

	NUMBER	DATE
--	--------	------

PRIORITY INFORMATION:	US 2002-387032P	20020607 (60)
	US 2002-430590P	20021203 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: MINTZ, LEVIN, COHN, FERRIS, GLOVSKY, AND POPEO, P.C.,
ONE FINANCIAL CENTER, BOSTON, MA, 02111

NUMBER OF CLAIMS: 77

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 4 Drawing Page(s)

LINE COUNT: 1654

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for islet neogenesis therapy comprising an EGF
and a **gastrin** in combination with immune suppression, and for
treating or preventing early stage **diabetes** with a
gastrin/CCK receptor ligand and an immunosuppressant are
provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 3 OF 6 USPATFULL on STN

ACCESSION NUMBER: 2002:185270 USPATFULL

TITLE: Prolonged efficacy of islet neogenesis therapy methods
with a **gastrin**/CCK receptor ligand and an EGF
receptor ligand composition in subjects with
preexisting **diabetes**

INVENTOR(S): Brand, Stephen J., Lincoln, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002098178	A1	20020725
APPLICATION INFO.:	US 2002-44048	A1	20020111 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-261638P	20010112 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Sonia K. Guterman, Esq., Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C, One Financial Center, Boston, MA, 02111	

NUMBER OF CLAIMS: 68

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 6 Drawing Page(s)

LINE COUNT: 1032

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods are provided for achieving in vivo islet cell
regeneration in subjects with preexisting **diabetes**. The
methods comprise short term treatment with a composition having a
gastrin/cholecystokinin receptor ligand and an EGF receptor
ligand. Treatment with such a composition for a short term resulted in a
prolonged period of increased insulin release, decreased fasting blood
glucose, and improved glucose tolerance, the prolonged efficacy, the
period being considered from the time of cessation of treatment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 4 OF 6 PCTFULL COPYRIGHT 2004 Univentio on STN

ACCESSION NUMBER: 2003103701 PCTFULL ED 20040102 EW 200351

TITLE (ENGLISH): COMPOSITIONS AND METHODS FOR TREATING DIABETES

TITLE (FRENCH): COMPOSITIONS ET PROCEDES DE TRAITEMENT DU DIABETE

INVENTOR(S): BRAND, Stephen, J., 161 Bedford Road, Lincoln, MA
01773, US [AU, US];
CRUZ, Antonio, 89 Dunloe Road, Toronto, Ontario M5P
2T7, CA [CA, CA]

PATENT ASSIGNEE(S): WARATAH PHARMACEUTICALS, INC., 415 Yonge Street, Suite 1103, Toronto, Ontario M5B 2E7, CA [CA, CA], for all designates States except US;
 BRAND, Stephen, J., 161 Bedford Road, Lincoln, MA 01773, US [AU, US], for US only;
 CRUZ, Antonio, 89 Dunloe Road, Toronto, Ontario M5P 2T7, CA [CA, CA], for US only
 AGENT: GUTERMAN, Sonia, K.\$, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111\$, US
 LANGUAGE OF FILING: English
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2003103701	A1	20031218

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
 CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
 IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
 MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE
 SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM
 ZW

RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW

RW (EAPO): AM AZ BY KG KZ MD RU TJ TM

RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU
 MC NL PT RO SE SI SK TR

RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2003-US18377 A 20030609

PRIORITY INFO.: US 2002-60/387,032 20020607

US 2002-60/430,590 20021203

ABEN Compositions and methods for islet neogenesis therapy comprising an EGF and a **gastrin** in combination with immune suppression, and for treating or preventing early stage **diabetes** with a **gastrin**/CCK receptor ligand and an immunosuppressant are provided.

ABFR L'invention porte sur des compositions et sur des procedes utilises dans la therapie de la neogenese des ilots pancreatiques, ces compositions comprenant un EGF et une gastrine en combinaison avec la suppression immune. Ces procedes consistent a traiter ou prevenir le diabete a un stade precoce avec un ligand recepteur de gastrine/CCK et un immunosuppresseur.

L12 ANSWER 5 OF 6 PCTFULL COPYRIGHT 2004 Univentio on STN

ACCESSION NUMBER: 2003100024 PCTFULL ED 20031215 EW 200349

TITLE (ENGLISH): TREATMENT FOR DIABETES

TITLE (FRENCH): TRAITEMENT DU DIABETE

INVENTOR(S): RABINOVITCH, Alex, 148-35 64th Ave, Edmonton, Alberta T6H 4Y1, CA [CA, CA];
 SUAREZ-PINZON, Wilma Lucia, 111-35 83rd Ave, Edmonton, Alberta T6G 2C6, CA [CO, CA];
 CRUZ, Antonio, 89 Dunloe Road, Toronto, Ontario M5P 2T7, CA [CA, CA];
 BRAND, Stephen J, 161 Bedford Road, Lincoln, MA 01733, US [US, AU]

PATENT ASSIGNEE(S): WARATAH PHARMACEUTICALS, INC., 415 Yonge Street, Suite 1103, Toronto, Ontario M5B 2E7, CA [CA, CA], for all designates States except US;
 UNIVERSITY OF ALBERTA, Department of Medicine, 430

Heritage Medical Research Centre, Edmonton, Alberta T6G 2S2, CA [CA, CA], for all designates States except US;
 RABINOVITCH, Alex, 148-35 64th Ave, Edmonton, Alberta T6H 4Y1, CA [CA, CA], for US only;
 SUAREZ-PINZON, Wilma Lucia, 111-35 83rd Ave, Edmonton, Alberta T6G 2C6, CA [CO, CA], for US only;
 CRUZ, Antonio, 89 Dunloe Road, Toronto, Ontario M5P 2T7, CA [CA, CA], for US only;
 BRAND, Stephen J, 161 Bedford Road, Lincoln, MA 01733, US [US, AU]

AGENT: RAE-VENTER, Barbara\$, P.O. Box 1898, Monterey, CA 93942\$, US

LANGUAGE OF FILING: English

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2003100024	A2	20031204

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
 CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
 IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
 MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE
 SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM
 ZW

RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW

RW (EAPO): AM AZ BY KG KZ MD RU TJ TM

RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU
 MC NL PT RO SE SI SK TR

RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2003-US16660 A 20030527

PRIORITY INFO.: US 2002-60/382,921 20020524

US 2002-60/384,357 20020530

ABEN Proliferating pancreatic islet cells obtained by the method of isolating a population of cells that preferably includes predominantly islet precursor cells that express one or more marker associated with an islet precursor cell and providing the precursor cells with one or more a pancreatic differentiation agent so that a population of cells is obtained that has a high proportion of cells with phenotypic characteristics of functional pancreatic islet β-cells. Optionally, the precursor cells are pretreated by providing them with one or more cell expansion agent to increase the number of cells in the population prior to differentiation. The pancreatic differentiation agent composition comprises a gastrin/CCK receptor ligand, e.g., a gastrin, in an amount sufficient to effect differentiation of pancreatic islet precursor cells to mature insulin-secreting cells. The cell expansion agent composition comprises one or more epidermal growth factor (EGF) receptor ligand in an amount sufficient to stimulate proliferation of the precursor cells. The methods of treatment include transplanting either undifferentiated precursor cells and providing the pancreatic differentiation agent either alone or in combination with the cell expansion agent in situ, or transplanting the functional pancreatic islet β-cells into the patient. The pancreatic islet β-cells can be used for drug screening, and replenishing pancreatic function in the context of clinical treatment.

ABFR L'invention concerne des cellules des ilots pancreatiques en mitose. Ces cellules sont obtenues par une methode consistant a isoler une population de cellules qui comprend de preference des cellules precurseur des ilots pancreatiques qui expriment un ou plusieurs

marqueurs associes a une cellule precurseur des ilots pancreatiques. Ces cellules precurseur comprennent un ou plusieurs agents de differentiation pancreatique permettant d'obtenir une population de cellules comportant une proportion de cellules ayant des caracteristiques phenotypiques de cellules β ; des ilots pancreatiques fonctionnelles. Si besoin, les cellules precurseur sont pretraitees en leur administrant un ou plusieurs agents d'expansion afin d'augmenter le nombre de cellules dans la population avant la differentiation. La composition d'agent de differentiation pancreatique comprend un ligand recepteur CCK/gastrine, p. ex., une gastrine, en quantite suffisante pour effectuer une differentiation des cellules precurseur des ilots pancreatiques pour faire murir les cellules qui secretent de l'insuline. La composition d'agents d'expansion de cellules comprend un ou plusieurs ligands recepteurs du facteur de croissance epidermique (EGF) en quantite suffisante pour stimuler la proliferation des cellules precurseur. Ces methodes de traitement consistent a greffer soit les cellules precurseur non differenciees et a liberer des agents de differenciation pancreatique seuls ou en combinaison avec l'agent d'expansion cellulaire in situ, soit a greffer les cellules β ; des ilots pancreatiques chez le patient. Ces cellules β ; des ilots pancreatiques peuvent etre utilisees dans le criblage de medicaments et dans la reconstitution de la fonction pancreatique dans le contexte de traitement clinique.

L12 ANSWER 6 OF 6 PCTFULL COPYRIGHT 2004 Univentio on STN
 ACCESSION NUMBER: 2002055152 PCTFULL ED 20020725 EW 200229
 TITLE (ENGLISH): PROLONGED EFFICACY OF ISLET NEOGENESIS THERAPY METHODS
 WITH A **GASTRIN**/CCK RECEPTOR LIGAND AND AN EGF
 RECEPTOR LIGAND COMPOSITION IN SUBJECTS WITH
 PREEXISTING **DIABETES**
 TITLE (FRENCH): EFFICACITE PROLONGEE DE METHODES DE SOINS DE NEOGENESE
 D'ILOT AVEC UNE COMPOSITION DE LIGAND DE RECEPTEUR DE
 GASTRINE/CCK ET DE LIGAND DE RECEPTEUR D'EGF CHEZ DES
 SUJETS A DIABETES PREEXISTANTS
 INVENTOR(S): BRAND, Stephen, J., 161 Bedford Road, Lincoln, MA
 01773, US
 PATENT ASSIGNEE(S): WARATAH PHARMACEUTICALS, INC., 1000 Roessler Road,
 Suite N, Woburn, MA 01801, US [US, CA]
 AGENT: GUTERMAN, Sonia, K.\$, Mintz, Levin, Cohn, Ferris,
 Glovsky and Popeo, P.C., One Financial Center, Boston,
 MA 02111\$, US
 LANGUAGE OF FILING: English
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002055152	A2	20020718

DESIGNATED STATES

W: AU CA JP
 RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
 TR

APPLICATION INFO.: WO 2002-US685 A 20020111
 PRIORITY INFO.: US 2001-60/261,638 20010112

ABEN Compositions and methods are provided for achieving in vivo islet cell regeneration in subjects with preexisting **diabetes**. The methods comprise short term treatment with a composition having a **gastrin**/cholecystokinin receptor ligand and an EGF receptor ligand. Treatment with such a composition for a short term resulted in a prolonged period of increased insulin release, decreased fasting blood

glucose, and improved glucose tolerance, the prolonged efficacy, the period being considered from the time of cessation of treatment.

ABFR L'invention concerne des compositions et des methodes permettant de realiser une regeneration cellulaire d'ilot <i>in vivo</i> chez des sujets a diabetes preexistants. Les methodes consistent en un traitement court terme avec une composition contenant un ligand de recepteur de gastrine/CCK (cholecystokinine) et un ligand de recepteur d'EGF (facteur de croissance epidermique). Un traitement court terme avec une telle composition resulte en une periode prolongee de liberation amelioree d'insuline, de diminution de la glycemie a jeun, et de tolerance au glucose amelioree, la duree de l'efficacite prolongee etant comptee a partir de la cessation du traitement.

=> d his

(FILE 'HOME' ENTERED AT 16:20:37 ON 14 APR 2004)

FILE 'MEDLINE, CAPLUS, SCISEARCH, BIOSIS, USPATFULL, PCTFULL' ENTERED AT 16:21:21 ON 14 APR 2004

```
L1      364 S GASTRIN(S)DIABETES
L2      584 S EGF(S)DIABETES
L3      268 S (ADMINISTER? OR TREAT OR TREATMENT) (S) (L1 OR L2)
L4      32 S L1(S)L2
L5      257 DUP REM L3 (11 DUPLICATES REMOVED)
L6      22 DUP REM L4 (10 DUPLICATES REMOVED)
L7      13 S GASTRIN(S) (LEU OR LEUCINE) (S) ((POSITION? OR RESIDUE OR ACID) (
L8      12 DUP REM L7 (1 DUPLICATE REMOVED)
L9      67 S EGF(S) ((DELET? (3W) (C(W) (TERMINUS OR TERMINAL))) OR (NEUTRAL(S
L10     53 DUP REM L9 (14 DUPLICATES REMOVED)
L11     2 S L10 AND L2
L12     6 S L1 AND L7
```

```
=> s (administer? or treat or treatment) (s) (l8 or l10)
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'TREATMENT) (S) (L70'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'TREATMENT) (S) (L73'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'TREATMENT) (S) (L76'
L13     27 (ADMINISTER? OR TREAT OR TREATMENT) (S) (L8 OR L10)
```

```
=> s (administer? or treat or treatment) (s) (l7 or l9)
L14     27 (ADMINISTER? OR TREAT OR TREATMENT) (S) (L7 OR L9)
```

```
=> dup rem l14
PROCESSING COMPLETED FOR L14
L15     27 DUP REM L14 (0 DUPLICATES REMOVED)
```

```
=> s l5 and l6
L16     16 L5 AND L6
```

=> d ibib abs 1-16

```
L16 ANSWER 1 OF 16      MEDLINE on STN
ACCESSION NUMBER: 2003169850      MEDLINE
DOCUMENT NUMBER: PubMed ID: 12688387
TITLE: Pharmacological treatment of chronic
diabetes by stimulating pancreatic beta-cell
regeneration with systemic co-administration of EGF
```

and **gastrin**.
 AUTHOR: Brand Stephen J; Tagerud Sven; Lambert Philip; Magil Sheila G; Tatarkiewicz Krystyna; Doiron Kathryn; Yan Yanhua
 CORPORATE SOURCE: Waratah Pharmaceuticals Corp, Woburn, MA 01801, USA..
 sbrand@attglobal.net
 SOURCE: Pharmacology & toxicology, (2002 Dec) 91 (6) 414-20. Ref: 19
 Journal code: 8702180. ISSN: 0901-9928.
 PUB. COUNTRY: Denmark
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 200304
 ENTRY DATE: Entered STN: 20030416
 Last Updated on STN: 20030423
 Entered Medline: 20030422

AB Transgenic expression of gastrin and EGF receptor ligands stimulates islet neogenesis in adult mice, significantly increasing islet mass. The present study aimed to determine whether pharmacological **treatment** with **gastrin** and **EGF** can significantly stimulate beta-cell regeneration in chronic, severe insulin-dependent **diabetes**. Diabetes was induced by intravenous streptozotocin, resulting in >95% beta cell destruction. Four weeks later, blood glucose levels were restored to normal range by exogenous insulin therapy and rats were treated with EGF/gastrin in combination, gastrin alone, or EGF alone given subcutaneously. After 14 days treatment blood glucose was significantly lower in the EGF/gastrin group compared to the untreated diabetic controls. Along with improved glucose tolerance, EGF/gastrin treatment significantly increased plasma C peptide and pancreatic insulin content compared to diabetic controls. Histological analysis showed that EGF/gastrin treatment significantly increased beta-cell mass as determined by point counting morphometrics. The EGF/gastrin group had a significantly greater number of BrdU labelled beta-cells/section consistent with stimulation of beta-cell replication or neogenesis. An increased number of gastrin receptor positive cells were observed in the EGF/gastrin-treated groups. In contrast to the effectiveness of the EGF/gastrin combination, neither gastrin nor EGF alone improved glucose tolerance in severely streptozotocin-diabetic rats. These studies indicate that physiologically significant improvement in glucose tolerance can be achieved through stimulating beta-cell regeneration with gastrin/EGF administered systemically as conventional pharmacological therapy.

L16 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2003:951166 CAPLUS
 DOCUMENT NUMBER: 140:13060
 TITLE: Treatment for diabetes
 INVENTOR(S): Brand, Stephen J.; Rabinovitch, Alex; Suarez-Pinzon, Wilma Lucia; Cruz, Antonio
 PATENT ASSIGNEE(S): Waratah Pharmaceuticals, Inc., Can.; University of Alberta
 SOURCE: PCT Int. Appl., 57 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003100024	A2	20031204	WO 2003-US16660	20030527
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 9476287	A1	19950808	AU 1994-76287	19940124
JP 09511384	T2	19971118	JP 1994-519519	19940124
EP 1132091	A1	20010912	EP 2001-114131	19940124
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
AT 222503	E	20020915	AT 1994-926459	19940124
ES 2185663	T3	20030501	ES 1994-926459	19940124
PRIORITY APPLN. INFO.:				
			US 2002-382921P	P 20020524
			US 2002-384357P	P 20020530
			EP 1994-926459	A3 19940124
			WO 1993-US12055	W 19940124

AB Proliferating pancreatic islet cells obtained by the method of isolating a population of cells that preferably includes predominantly islet precursor cells that express one or more marker associated with an islet precursor cell and providing the precursor cells with one or more a pancreatic differentiation agent so that a population of cells is obtained that has a high proportion of cells with phenotypic characteristics of functional pancreatic islet β -cells. Optionally, the precursor cells are pretreated by providing them with one or more cell expansion agent to increase the number of cells in the population prior to differentiation. The pancreatic differentiation agent composition comprises a gastrin/CCK receptor ligand, e.g., a gastrin, in an amount sufficient to effect differentiation of pancreatic islet precursor cells to mature insulin-secreting cells. The cell expansion agent composition comprises one or more epidermal growth factor (EGF) receptor ligand in an amount sufficient to stimulate proliferation of the precursor cells. The methods of treatment include transplanting either undifferentiated precursor cells and providing the pancreatic differentiation agent either alone or in combination with the cell expansion agent in situ, or transplanting the functional pancreatic islet β -cells into the patient. The pancreatic islet β -cells can be used for drug screening, and replenishing pancreatic function in the context of clin. treatment.

L16 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:348744 CAPLUS

DOCUMENT NUMBER: 138:332215

TITLE: **Treatment of diabetes with a gastrin receptor or an EGF receptor ligand to cause differentiation of pancreatic islet precursor cells into mature insulin-secreting cells**

INVENTOR(S): Parikh, Indu; Lane, Anne; Nardi, Ronald V.; Brand, Stephen J.

PATENT ASSIGNEE(S): Waratah Pharmaceuticals, Inc., Can.; The General Hospital Corporation

SOURCE: U.S., 20 pp., Cont.-in-part of U.S. 6,288,301.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6558952	B1	20030506	US 1999-241100	19990129
US 5885956	A	19990323	US 1992-992255	19921214
AU 9476287	A1	19950808	AU 1994-76287	19940124
EP 752882	A1	19970115	EP 1994-926459	19940124
EP 752882	B1	20020821		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 09511384	T2	19971118	JP 1994-519519	19940124
EP 1132091	A1	20010912	EP 2001-114131	19940124
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
AT 222503	E	20020915	AT 1994-926459	19940124
ES 2185663	T3	20030501	ES 1994-926459	19940124
US 6288301	B1	20010911	US 1998-127028	19980730
CA 2326741	AA	20000803	CA 1999-2326741	19991027
WO 2000044400	A1	20000803	WO 1999-US25463	19991027
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1071447	A1	20010131	EP 1999-956786	19991027
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2004506591	T2	20040304	JP 2000-595702	19991027
SE 2000003508	A	20001121	SE 2000-3508	20000929
US 2002081285	A1	20020627	US 2001-29551	20011220
US 2004037818	A1	20040226	US 2003-446612	20030527

PRIORITY APPLN. INFO.:

US 1992-992255	A1	19921214
US 1998-127028	A2	19980730
EP 1994-926459	A3	19940124
WO 1993-US12055	W	19940124
US 1999-241100	A	19990129
WO 1999-US25463	W	19991027
US 2001-29551	A2	20011220
US 2002-382921P	P	20020524
US 2002-384357P	P	20020530

AB Methods and compns. for treating diabetes mellitus in a patient in need thereof are provided. The methods include administering to a patient a composition providing a gastrin/CCK receptor ligand, e.g., a gastrin, and/or an epidermal growth factor (EGF) receptor ligand, e.g., TGF- α , in an amount sufficient to effect differentiation of pancreatic islet precursor cells to mature insulin-secreting cells. The composition can be administered systemically or expressed in situ by cells transgenically supplemented with one or both of a gastrin/CCK receptor ligand gene, e.g., a preprogastrin peptide precursor gene and an EGF receptor ligand gene, e.g., a TGF- α gene. The methods also include transplanting into a patient cultured pancreatic islets in which mature insulin-secreting beta cells are proliferated by exposure to a gastrin/CCK receptor ligand and an EGF receptor ligand.

REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:539568 CAPLUS
 DOCUMENT NUMBER: 137:103902
 TITLE: Prolonged efficacy of islet neogenesis therapy methods
 with a **gastrin**/CCK receptor ligand and an
EGF receptor ligand composition in subjects
 with preexisting **diabetes**
 INVENTOR(S): Brand, Stephen J.
 PATENT ASSIGNEE(S): Waratah Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 33 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002055152	A2	20020718	WO 2002-US685	20020111
WO 2002055152	C1	20021114		
WO 2002055152	C2	20030123		
WO 2002055152	A3	20030410		
W: AU, CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
US 2002098178	A1	20020725	US 2002-44048	20020111
EP 1351742	A2	20031015	EP 2002-708990	20020111
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				

PRIORITY APPLN. INFO.: US 2001-261638P P 20010112
 WO 2002-US685 W 20020111

AB Comps. and methods are provided for achieving in vivo islet cell regeneration in subjects with preexisting diabetes. The methods comprise short term treatment with a composition having a gastrin/cholecystokinin receptor ligand and an EGF receptor ligand. Treatment with such a composition for a short term resulted in a prolonged period of increased insulin release, decreased fasting blood glucose, and improved glucose tolerance, the prolonged efficacy, the period being considered from the time of cessation of treatment.

L16 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:535013 CAPLUS
 DOCUMENT NUMBER: 133:130276
 TITLE: **Treatment of diabetes** with a
gastrin receptor ligand or an **EGF**
 receptor ligand to cause differentiation of pancreatic
 islet precursor cells to mature insulin-secreting
 cells
 INVENTOR(S): Parikh, Indu; Lane, Anne; Nardi, Ronald V.; Brand,
 Stephen J.
 PATENT ASSIGNEE(S): RTP Pharma Inc., Can.; General Hospital Corporation
 SOURCE: PCT Int. Appl., 50 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

```

-----
WO 2000044400      A1      20000803      WO 1999-US25463  19991027
W:  AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
    DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
    JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
    MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
    TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD,
    RU, TJ, TM
RW:  GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
    DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
    CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
AU 9476287          A1      19950808          AU 1994-76287      19940124
JP 09511384         T2      19971118          JP 1994-519519    19940124
EP 1132091          A1      20010912          EP 2001-114131    19940124
R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE
AT 222503           E       20020915          AT 1994-926459    19940124
ES 2185663          T3      20030501          ES 1994-926459    19940124
US 6558952          B1      20030506          US 1999-241100    19990129
CA 2326741          AA      20000803          CA 1999-2326741   19991027
EP 1071447          A1      20010131          EP 1999-956786    19991027
R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
    IE, FI
JP 2004506591       T2      20040304          JP 2000-595702    19991027
SE 2000003508       A       20001121          SE 2000-3508      20000929
PRIORITY APPLN. INFO.:
US 1999-241100      A       19990129
US 1992-992255      A1      19921214
EP 1994-926459      A3      19940124
WO 1993-US12055     W       19940124
US 1998-127028      A2      19980730
WO 1999-US25463     W       19991027

```

AB Methods and compns. for treating diabetes mellitus in a patient in need thereof are provided. The methods include administering to a patient a composition providing a gastrin/CCK receptor ligand, e.g., a gastrin, and/or an epidermal growth factor (EGF) receptor ligand, e.g., TGF- α , in an amount sufficient to effect differentiation of pancreatic islet precursor cells to mature insulin-secreting cells. The composition can be administered systemically or expressed in situ by cells transgenically supplemented with one or both of a gastrin/CCK receptor ligand gene, e.g., a preprogastrin peptide precursor gene and an EGF receptor ligand gene, e.g., a TGF- α gene. The methods also include transplanting into a patient cultured pancreatic islets in which mature insulin-secreting beta cells are proliferated by exposure to a gastrin/CCK receptor ligand and an EGF receptor ligand.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 6 OF 16. CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1995:795113 CAPLUS

DOCUMENT NUMBER: 123:188615

TITLE: **Treatment of juvenile diabetes**
with ligands of **gastrin/CCK** receptors and
EGF receptors

INVENTOR(S): Nardi, Ronald V.; Brand, Stephen J.

PATENT ASSIGNEE(S): Research Triangle Pharmaceuticals, Ltd., USA

SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 26 pp.
CODEN: CNXXEV

DOCUMENT TYPE: Patent

LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1098942	A	19950222	CN 1993-112658	19931214
US 5885956	A	19990323	US 1992-992255	19921214
CA 2182034	AA	19950727	CA 1994-2182034	19940124
AU 9476287	A1	19950808	AU 1994-76287	19940124
EP 752882	A1	19970115	EP 1994-926459	19940124
EP 752882	B1	20020821		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 09511384	T2	19971118	JP 1994-519519	19940124
EP 1132091	A1	20010912	EP 2001-114131	19940124
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
AT 222503	E	20020915	AT 1994-926459	19940124
ES 2185663	T3	20030501	ES 1994-926459	19940124
AU 722004	B2	20000720	AU 1996-64254	19960823
AU 9664254	A1	19980226		

PRIORITY APPLN. INFO.:

US 1992-992255	A	19921214
EP 1994-926459	A3	19940124
WO 1993-US12055	W	19940124

AB A method for treating juvenile **diabetes** using a combination of the ligands for **gastrin**/CCK receptors and the ligands for **EGF** receptors to induce the differentiation of pancreatic precursor cells is described. The pancreatic precursor cells can be introduced in vitro with the genes encoding the ligands, e.g., gastrin and TGF α . The treated cells can then be re-introduced into the mammalian host. Expression of human gastrin exons 2 and 3 and TGF α in a mouse model, along with their biol. effects, was demonstrated.

L16 ANSWER 7 OF 16 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN'

ACCESSION NUMBER: 2002:558791 BIOSIS

DOCUMENT NUMBER: PREV200200558791

TITLE: Effective **treatment** of chronic **diabetes** by stimulating pancreatic beta cell regeneration with **gastrin/EGF** therapy.

AUTHOR(S): Brand, S. J. [Reprint author]; Lambert, P. D. [Reprint author]; Magil, S. G. [Reprint author]; Tartarkiewicz, K. [Reprint author]; Doiron, K. [Reprint author]; Kopec, K. [Reprint author]; Howard, W. [Reprint author]; Yan, Y. [Reprint author]

CORPORATE SOURCE: Waratah Pharmaceuticals Corp., Woburn, MA, USA
SOURCE: Regulatory Peptides, (15 August, 2002) Vol. 108, No. 1, pp. 31. print.

Meeting Info.: 14th International Symposium on Regulatory Peptides. Boston, MA, USA. August 31-September 03, 2002.
CODEN: REPPDY. ISSN: 0167-0115.

DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)

LANGUAGE: English

ENTRY DATE: Entered STN: 30 Oct 2002

Last Updated on STN: 30 Oct 2002

L16 ANSWER 8 OF 16 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN

ACCESSION NUMBER: 2001:534404 BIOSIS

DOCUMENT NUMBER: PREV200100534404

TITLE: Treatment for juvenile diabetes.

AUTHOR(S): Nardi, Ronald V. [Inventor, Reprint author]; Brand, Stephen J. [Inventor]

CORPORATE SOURCE: Sudbury, MA, USA
ASSIGNEE: Waratah Pharmaceuticals, Inc., Canada; The

General Hospital Corporation

PATENT INFORMATION: US 6288301 September 11, 2001

SOURCE: Official Gazette of the United States Patent and Trademark
Office Patents, (Sep. 11, 2001) Vol. 1250, No. 2. e-file.
CODEN: OGUPE7. ISSN: 0098-1133.

DOCUMENT TYPE: Patent

LANGUAGE: English

ENTRY DATE: Entered STN: 14 Nov 2001

Last Updated on STN: 23 Feb 2002

AB A method for treating **diabetes** mellitus by **administering** composition providing a **gastrin**/CCK receptor ligand, e.g. a **gastrin**, and an **EGF** receptor ligand, e.g. TGFalpha, in an amount sufficient to effect differentiation of pancreatic islet precursor cells to mature insulin-secreting cells. The composition can be administered systemically or expressed in situ by cells transgenically supplemented with one or both of a gastrin/CCK receptor ligand gene, e.g. a preprogastrin peptide precursor gene and an EGF receptor ligand gene, e.g. a TGFalpha gene.

L16 ANSWER 9 OF 16 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN

ACCESSION NUMBER: 1999:178019 BIOSIS

DOCUMENT NUMBER: PREV199900178019

TITLE: **Treatment for diabetes** using a **gastrin**/CCK receptor ligand and an **EGF** receptor ligand.

AUTHOR(S): Nardi, R. V [Inventor]; Brand, S. J. [Inventor]

CORPORATE SOURCE: Sudbury, Mass., USA

ASSIGNEE: RESEARCH TRIANGLE PHARMACEUTICALS, AND THE
GENERAL HOSPITAL CORPORATION

PATENT INFORMATION: US 5885956 March 23, 1999

SOURCE: Official Gazette of the United States Patent and Trademark
Office Patents, (March 23, 1999) Vol. 1220, No. 4, pp.
3549. print.

CODEN: OGUPE7. ISSN: 0098-1133.

DOCUMENT TYPE: Patent

LANGUAGE: English

ENTRY DATE: Entered STN: 5 May 1999

Last Updated on STN: 5 May 1999

L16 ANSWER 10 OF 16 USPATFULL on STN

ACCESSION NUMBER: 2004:50392 USPATFULL

TITLE: Treatment for diabetes

INVENTOR(S): Brand, Stephen J., Lincoln, MA, UNITED STATES

Cruz, Antonio, Toronto, CANADA

Rabinovitch, Alex, Edmonton, CANADA

Suarez-Pinzon, Wilma Lucia, Edmonton, CANADA

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION:	US 2004037818	A1	20040226
---------------------	---------------	----	----------

APPLICATION INFO.:	US 2003-446612	A1	20030527 (10)
--------------------	----------------	----	---------------

RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-29551, filed on 20 Dec 2001, PENDING Continuation of Ser. No. US 1999-241100, filed on 29 Jan 1999, GRANTED, Pat. No. US 6558952 Continuation-in-part of Ser. No. US 1998-127028, filed on 30 Jul 1998, GRANTED, Pat. No. US 6288301		
-----------------------	---	--	--

NUMBER	DATE
--------	------

PRIORITY INFORMATION: US 2002-384357P 20020530 (60)
 US 2002-382921P 20020524 (60)
 DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: RAE-VENTER LAW GROUP, P.C., P.O. BOX 1898, MONTEREY,
 CA, 93942-1898
 NUMBER OF CLAIMS: 20
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 16 Drawing Page(s)
 LINE COUNT: 1522

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Proliferating pancreatic islet cells obtained by the method of isolating a population of cells that preferably includes predominantly islet precursor cells that express one or more marker associated with an islet precursor cell and providing the precursor cells with one or more a pancreatic differentiation agent so that a population of cells is obtained that has a high proportion of cells with phenotypic characteristics of functional pancreatic islet β -cells. Optionally, the precursor cells are pretreated by providing them with one or more cell expansion agent to increase the number of cells in the population prior to differentiation. The pancreatic differentiation agent composition comprises a gastrin/CCK receptor ligand, e.g., a gastrin, in an amount sufficient to effect differentiation of pancreatic islet precursor cells to mature insulin-secreting cells. The cell expansion agent composition comprises one or more epidermal growth factor (EGF) receptor ligand in an amount sufficient to stimulate proliferation of the precursor cells. The methods of treatment include transplanting either undifferentiated precursor cells and providing the pancreatic differentiation agent either alone or in combination with the cell expansion agent in situ, or transplanting the functional pancreatic islet β -cells into the patient. The pancreatic islet β -cells can be used for drug screening, and replenishing pancreatic function in the context of clinical treatment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 11 OF 16 USPATFULL on STN
 ACCESSION NUMBER: 2004:31743 USPATFULL
 TITLE: Compositions and methods for treating diabetes
 INVENTOR(S): Brand, Stephen J., Lincoln, MA, UNITED STATES
 Cruz, Antonio, Toronto, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004023885	A1	20040205
APPLICATION INFO.:	US 2003-457126	A1	20030609 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-387032P	20020607 (60)
	US 2002-430590P	20021203 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MINTZ, LEVIN, COHN, FERRIS, GLOVSKY, AND POPEO, P.C., ONE FINANCIAL CENTER, BOSTON, MA, 02111	
NUMBER OF CLAIMS:	77	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	1654	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for islet neogenesis therapy comprising an **EGF** and a **gastrin** in combination with immune suppression, and for treating or preventing early stage **diabetes** with a **gastrin**/CCK receptor ligand and an immunosuppressant are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 12 OF 16 USPATFULL on STN

ACCESSION NUMBER: 2002:185270 USPATFULL
 TITLE: Prolonged efficacy of islet neogenesis therapy methods with a **gastrin**/CCK receptor ligand and an **EGF** receptor ligand composition in subjects with preexisting **diabetes**
 INVENTOR(S): Brand, Stephen J., Lincoln, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002098178	A1	20020725
APPLICATION INFO.:	US 2002-44048	A1	20020111 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-261638P	20010112 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Sonia K. Guterman, Esq., Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C, One Financial Center, Boston, MA, 02111	
NUMBER OF CLAIMS:	68	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Page(s)	
LINE COUNT:	1032	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods are provided for achieving in vivo islet cell regeneration in subjects with preexisting **diabetes**. The methods comprise short term **treatment** with a composition having a **gastrin**/cholecystokinin receptor ligand and an **EGF** receptor ligand. **Treatment** with such a composition for a short term resulted in a prolonged period of increased insulin release, decreased fasting blood glucose, and improved glucose tolerance, the prolonged efficacy, the period being considered from the time of cessation of **treatment**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 13 OF 16 USPATFULL on STN

ACCESSION NUMBER: 2002:156690 USPATFULL
 TITLE: Treatment for diabetes
 INVENTOR(S): Parikh, Indu, Chapel Hill, NC, UNITED STATES
 Lane, Anne, Westmount, CANADA
 Nardi, Ronald V., Nahwah, NJ, UNITED STATES
 Brand, Stephen J., Lincoln, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002081285	A1	20020627
APPLICATION INFO.:	US 2001-29551	A1	20011220 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-241100, filed on 29 Jan 1999, PENDING Continuation-in-part of Ser. No. US		

1998-127028, filed on 30 Jul 1998, PATENTED
Continuation of Ser. No. US 1992-992255, filed on 14
Dec 1992, PATENTED

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Rae-Venter Law Group, P.C., P.O. Box 60039, Palo Alto,
CA, 94306
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Page(s)
LINE COUNT: 1274

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and compositions for treating **diabetes** mellitus in a patient in need thereof are provided. The methods include **administering** to a patient a composition providing a **gastrin**/CCK receptor ligand, e.g., a **gastrin**, and/or an epidermal growth factor (**EGF**) receptor ligand, e.g., TGF- α , in an amount sufficient to effect differentiation of pancreatic islet precursor cells to mature insulin-secreting cells. The composition can be **administered** systemically or expressed in situ by cells transgenically supplemented with one or both of a **gastrin**/CCK receptor ligand gene, e.g., a preprogastrin peptide precursor gene and an **EGF** receptor ligand gene, e.g., a TGF- α gene. The methods also include transplanting into a patient cultured pancreatic islets in which mature insulin-secreting beta cells are proliferated by exposure to a **gastrin**/CCK receptor ligand and an **EGF** receptor ligand.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 14 OF 16 PCTFULL COPYRIGHT 2004 Univentio on STN
ACCESSION NUMBER: 2004004661 PCTFULL ED 20040122 EW 200403
TITLE (ENGLISH): BOROPROLINE COMPOUND COMBINATION THERAPY
TITLE (FRENCH): POLYTHERAPIE A BASE DE COMPOSES DE BOROPROLINE
INVENTOR(S): ADAMS, Sharlene, 45 Rosemont Avenue, Waltham, MA 02451,
US;
MILLER, Glenn, T., 63 Bearhill Road, Merrimac, MA
01860, US;
JESSON, Michael, I., 19 Plain Street, Hopedale, MA
01747, US;
JONES, Barry, 80 Wndell, No.3, Cambridge, MA 02138, US
PATENT ASSIGNEE(S): POINT THERAPEUTICS, INC., 125 Summer Street, Suite
1840, Boston, MA 02111, US [US, US]
AGENT: TREVISAN, Maria, A.\$, Wolf, Greenfield & Sacks, P.C.,
600 Atlantic Avenue, Boston, MA 02210\$, US
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2004004661	A2	20040115

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD
SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA
ZM ZW

RW (ARIPO):

GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW

RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
 RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU
 MC NL PT RO SE SI SK TR
 RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
 APPLICATION INFO.: WO 2003-US21547 A 20030709
 PRIORITY INFO.: US 2002-60/394,856 20020709
 US 2002-60/414,978 20021001
 US 2003-60/466,435 20030428

ABEN A method is provided for treating subjects with combination therapy including compounds of Formula I. It was surprisingly discovered that this combination enhanced the efficacy of both agents, and that administration of Formula I compounds induced cytokine and chemokine production in vivo. The combinations can be used to enhance ADCC, stimulate immune responses and/or patient and treat certain disorders. The invention also relates to kits and compositions relating to such combinations.

ABFR Cette invention se rapporte a un procede servant a traiter des sujets au moyen d'une polytherapie utilisant des composés representés par la formule (I). On a decouvert de facon surprenante que cette polytherapie améliore l'efficacité des deux agents, et que l'administration de composés de formule (I) induit la production de cytokine et de chimiokine in vivo. Ces polytherapies peuvent être utilisées pour améliorer la cytotoxicité médiée par des cellules dépendant des anticorps (ADCC), pour stimuler les réactions immunitaires et/ou l'organisme du patient et pour traiter certains troubles. Cette invention concerne également des kits et des compositions associées a ces polytherapies.

L16 ANSWER 15 OF 16 PCTFULL COPYRIGHT 2004 Univentio on STN
 ACCESSION NUMBER: 2000059525 PCTFULL ED 20020515
 TITLE (ENGLISH): USE OF ErbB RECEPTOR LIGANDS IN TREATING DIABETES
 TITLE (FRENCH): UTILISATION DE LIGANDS RECEPTEURS DE ErbB DANS LE
 TRAITEMENT DU DIABETE
 INVENTOR(S): HUANG, Xiaojian;
 STEWART, Timothy, Andrew
 PATENT ASSIGNEE(S): GENENTECH, INC.
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2000059525	A2	20001012

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ
 DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS
 JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN
 MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT
 TZ UA UG UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG
 ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI
 FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN
 GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2000-US9240 A 20000405
 PRIORITY INFO.: US 1999-60/128,017 19990406

ABEN The invention provides methods for treating pancreatic dysfunction, particularly diabetes, in mammals using ErbB receptor ligands, such as heregulin, betacellulin, and EGF. Methods of treating such conditions using anti-ErbB receptor agonist antibodies are further provided. The methods of the invention may be performed by direct administration of such

therapeutically useful agents to mammals, or alternatively, by exposing certain pancreatic cell types to such agents i(in vitro) and subsequently transplanting the treated cells to a mammal.

ABFR Cette invention concerne des methodes de traitement du dysfonctionnement pancreatique, en particulier du diabete, chez les mammiferes, au moyen de ligands recepteurs ErbB, tels que l'hereguline, la betacelluline et EGF. L'invention concerne egalement des methodes de traitement de ces pathologies au moyen d'anticorps agonistes anti-recepteur ErbB. Selon l'invention, on peut administrer directement ces agents utiles au plan therapeutique a des mammifere, ou, en variante, exposer certains types de cellules pancreatiques a de tels agents i(in vitro) et transplanter ulterieurement les cellules traitees dans un mammiferes.

L16 ANSWER 16 OF 16 PCTFULL COPYRIGHT 2004 Univentio on STN

ACCESSION NUMBER: 1995019785 PCTFULL ED 20020514

TITLE (ENGLISH): TREATMENT FOR JUVENILE DIABETES

TITLE (FRENCH): TRAITEMENT DU DIABETE JUVENILE

INVENTOR(S): NARDI, Ronald, V.;

BRAND, Stephen, J.

PATENT ASSIGNEE(S): RESEARCH TRIANGLE PHARMACEUTICALS LTD.

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9519785	A1	19950727

DESIGNATED STATES

W: AU CA JP KR RU AT BE CH DE DK ES FR GB GR IE IT LU MC
NL PT SE

APPLICATION INFO.: WO 1994-US12055 A 19940124

ABEN A method for treating **diabetes** mellitus by **administering** composition providing a **gastrin**/CCK receptor ligand, e.g. a **gastrin**, and an **EGF** receptor ligand, e.g. 'TGF'alpha', in an amount sufficient to effect differentiation of pancreatic islet precursor cells to mature insulin-secreting cells. The composition can be **administered** systemically or expressed in situ by cells transgenically supplemented with one or both of a **gastrin**/CCK receptor ligand gene, e.g. a preprogastrin peptide precursor gene and an **EGF** receptor ligand gene, e.g. a 'TGF'alpha' gene.

ABFR L'invention concerne un procede de traitement du diabete sucre, consistant a administrer une composition contenant un ligand au recepteur de gastrine/cystokinine (CCK), par exemple une gastrine, et un ligand au recepteur d'un facteur de croissance epidermique, par exemple le facteur de croissance transformant 'alpha', en une quantite suffisante pour que se fasse la differenciation de cellules precurseurs d'ilots pancreatiques en cellules mures secretant de l'insuline. Cette composition peut etre administree par voix generale ou exprimee in situ par des cellules transgeniquement completees par au moins un des genes suivants: un gene

de ligand au recepteur de
gastrine/CCK, par exemple un gene precurseur peptidique de
preprogastrine, et un gene de ligand au
recepteur d'un facteur de croissance epidermique, par exemple un gene du
facteur de croissance
transformant 'alpha'.

=> d his

(FILE 'HOME' ENTERED AT 16:20:37 ON 14 APR 2004)

FILE 'MEDLINE, CAPLUS, SCISEARCH, BIOSIS, USPATFULL, PCTFULL' ENTERED AT
16:21:21 ON 14 APR 2004

L1 364 S GASTRIN(S)DIABETES
L2 584 S EGF(S)DIABETES
L3 268 S (ADMINISTER? OR TREAT OR TREATMENT) (S) (L1 OR L2)
L4 32 S L1(S)L2
L5 257 DUP REM L3 (11 DUPLICATES REMOVED)
L6 22 DUP REM L4 (10 DUPLICATES REMOVED)
L7 13 S GASTRIN(S) (LEU OR LEUCINE) (S) ((POSITION? OR RESIDUE OR ACID) (
L8 12 DUP REM L7 (1 DUPLICATE REMOVED)
L9 67 S EGF(S) ((DELET? (3W) (C(W) (TERMINUS OR TERMINAL))) OR (NEUTRAL(S
L10 53 DUP REM L9 (14 DUPLICATES REMOVED)
L11 2 S L10 AND L2
L12 6 S L1 AND L7
L13 27 S (ADMINISTER? OR TREAT OR TREATMENT) (S) (L8 OR L10)
L14 27 S (ADMINISTER? OR TREAT OR TREATMENT) (S) (L7 OR L9)
L15 27 DUP REM L14 (0 DUPLICATES REMOVED)
L16 16 S L5 AND L6

=> d ibib abs 1-27 l15

L15 ANSWER 1 OF 27 USPATFULL on STN
ACCESSION NUMBER: 2004:50392 USPATFULL
TITLE: Treatment for diabetes
INVENTOR(S): Brand, Stephen J., Lincoln, MA, UNITED STATES
Cruz, Antonio, Toronto, CANADA
Rabinovitch, Alex, Edmonton, CANADA
Suarez-Pinzon, Wilma Lucia, Edmonton, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004037818	A1	20040226
APPLICATION INFO.:	US 2003-446612	A1	20030527 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-29551, filed on 20 Dec 2001, PENDING Continuation of Ser. No. US 1999-241100, filed on 29 Jan 1999, GRANTED, Pat. No. US 6558952 Continuation-in-part of Ser. No. US 1998-127028, filed on 30 Jul 1998, GRANTED, Pat. No. US 6288301		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-384357P	20020530 (60)
	US 2002-382921P	20020524 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	RAE-VENTER LAW GROUP, P.C., P.O. BOX 1898, MONTEREY, CA, 93942-1898	

NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 16 Drawing Page(s)
LINE COUNT: 1522

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Proliferating pancreatic islet cells obtained by the method of isolating a population of cells that preferably includes predominantly islet precursor cells that express one or more marker associated with an islet precursor cell and providing the precursor cells with one or more a pancreatic differentiation agent so that a population of cells is obtained that has a high proportion of cells with phenotypic characteristics of functional pancreatic islet β -cells. Optionally, the precursor cells are pretreated by providing them with one or more cell expansion agent to increase the number of cells in the population prior to differentiation. The pancreatic differentiation agent composition comprises a gastrin/CCK receptor ligand, e.g., a gastrin, in an amount sufficient to effect differentiation of pancreatic islet precursor cells to mature insulin-secreting cells. The cell expansion agent composition comprises one or more epidermal growth factor (EGF) receptor ligand in an amount sufficient to stimulate proliferation of the precursor cells. The methods of treatment include transplanting either undifferentiated precursor cells and providing the pancreatic differentiation agent either alone or in combination with the cell expansion agent in situ, or transplanting the functional pancreatic islet β -cells into the patient. The pancreatic islet β -cells can be used for drug screening, and replenishing pancreatic function in the context of clinical treatment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 2 OF 27 USPATFULL on STN
ACCESSION NUMBER: 2004:31743 USPATFULL
TITLE: Compositions and methods for treating diabetes
INVENTOR(S): Brand, Stephen J., Lincoln, MA, UNITED STATES
Cruz, Antonio, Toronto, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004023885	A1	20040205
APPLICATION INFO.:	US 2003-457126	A1	20030609 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-387032P	20020607 (60)
	US 2002-430590P	20021203 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MINTZ, LEVIN, COHN, FERRIS, GLOVSKY, AND POPEO, P.C., ONE FINANCIAL CENTER, BOSTON, MA, 02111	
NUMBER OF CLAIMS:	77	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	1654	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for islet neogenesis therapy comprising an EGF and a gastrin in combination with immune suppression, and for treating or preventing early stage diabetes with a gastrin/CCK receptor ligand and an immunosuppressant are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 3 OF 27 PCTFULL COPYRIGHT 2004 Univentio on STN
 2004009622 PCTFULL ED 20040204 EW 200405
 ACCESSION NUMBER: PROTEIN COMPLEXES OF CELLULAR NETWORKS UNDERLYING THE
 DEVELOPMENT OF CANCER AND OTHER DISEASES
 TITLE (ENGLISH): COMPLEXES DE PROTEINIQUES DE RESEAUX CELLULAIRES
 FONDANT LE DEVELOPPEMENT DU CANCER ET D'AUTRES MALADIES
 TITLE (FRENCH):
 INVENTOR(S): MERINO, Alejandro, Kleine Mantelgasse 21, 69117
 Heidelberg, DE [CL, DE];
 BOUWMEESTER, Tewis, Bergstr. 1, 69120 Heidelberg, DE
 [NL, DE];
 BAUER, Andreas, Dammweg 9, 69123 Heidelberg, DE [DE,
 DE];
 DREWES, Gerard, Schiffgasse 6, 69117 Heidelberg, DE
 [NL, DE];
 MARZIOCH, Martina, Berghalde 34, 69126 Heidelberg, DE
 [DE, DE];
 KRUSE, Ulrich, Frankenweg 32, 69221 Dossenheim, DE [DE,
 DE];
 SUPERTI-FURGA, Giulio, Muehldamm 7, 69118 Heidelberg,
 DE [IT, DE];
 EBERHARD, Dirk, Daniel-Hartmann-Str. 7, 69256 Mauer, DE
 [DE, DE];
 RUFFNER, Heinz, Reilsheimer Str. 42/1, 69245 Bammental,
 DE [CH, DE];
 HOBSON, Scott, Bismarckstr. 47, 69198 Schriesheim, DE
 [US, DE];
 HELFTENBEIN, Gerd, Nieder-Ohmener Str. 16, 35329
 Gmuenden, DE [DE, DE];
 CRUCIAT, Cristina, Taunusstr. 10, 64289 Darmstadt, DE
 [DE, DE]
 PATENT ASSIGNEE(S): CELLZOME AG, Meyerhofstrasse 1, 69117 Heidelberg, DE
 [DE, DE], for all designates States except US;
 MERINO, Alejandro, Kleine Mantelgasse 21, 69117
 Heidelberg, DE [CL, DE], for US only;
 BOUWMEESTER, Tewis, Bergstr. 1, 69120 Heidelberg, DE
 [NL, DE], for US only;
 BAUER, Andreas, Dammweg 9, 69123 Heidelberg, DE [DE,
 DE], for US only;
 DREWES, Gerard, Schiffgasse 6, 69117 Heidelberg, DE
 [NL, DE], for US only;
 MARZIOCH, Martina, Berghalde 34, 69126 Heidelberg, DE
 [DE, DE], for US only;
 KRUSE, Ulrich, Frankenweg 32, 69221 Dossenheim, DE [DE,
 DE], for US only;
 SUPERTI-FURGA, Giulio, Muehldamm 7, 69118 Heidelberg,
 DE [IT, DE], for US only;
 EBERHARD, Dirk, Daniel-Hartmann-Str. 7, 69256 Mauer, DE
 [DE, DE], for US only;
 RUFFNER, Heinz, Reilsheimer Str. 42/1, 69245 Bammental,
 DE [CH, DE], for US only;
 HOBSON, Scott, Bismarckstr. 47, 69198 Schriesheim, DE
 [US, DE], for US only;
 HELFTENBEIN, Gerd, Nieder-Ohmener Str. 16, 35329
 Gmuenden, DE [DE, DE], for US only;
 CRUCIAT, Cristina, Taunusstr. 10, 64289 Darmstadt, DE
 [DE, DE], for US only
 AGENT: HUHNS, Michael\$, Isenbruck, Boesl, Hoerschler, Wichmann,
 Huhn, Theodor-Heuss-Anlage 12, 68165 Mannheim\$, DE
 LANGUAGE OF FILING: English

LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2004009622	A2	20040129
DESIGNATED STATES			
W:	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW		
RW (ARIPO):	GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW		
RW (EAPO):	AM AZ BY KG KZ MD RU TJ TM		
RW (EPO):	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR		
RW (OAPI):	BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2003-EP7835	A	20030718
PRIORITY INFO.:	EP 2002-02 016 109.7		20020719
	EP 2002-02 016 128.7		20020719
	EP 2002-02 016 123.8		20020719
	EP 2002-02 016 111.3		20020719
	EP 2002-02 016 427.3		20020722

ABEN The present invention relates to protein complexes involved in cellular processes which have been shown to be critical for the development of various forms of cancer, component proteins of the said complexes, fragments and derivatives of the component proteins, and antibodies specific to the complexes. The present invention also relates to methods for use of the complexes and their interacting proteins in, inter alia, screening, diagnosis, and therapy, as well as to methods of preparing the complexes.

ABFR La presente invention concerne des complexes proteiniques qui entrent en jeu dans des processus cellulaires qui se sont avérés critiques pour le développement de diverses formes de cancer, des protéines composant de ces complexes, des fragments et des dérivés de ces protéines composant et, des anticorps spécifiques de ces complexes. Cette invention concerne aussi des techniques d'utilisation de ces complexes et leur protéines d'interaction dans la recherche, le diagnostic et la thérapie, entre autres domaines d'utilisation, ainsi que des techniques de préparation de ces complexes.

L15 ANSWER 4 OF 27 USPATFULL on STN

ACCESSION NUMBER: 2003:237907 USPATFULL
TITLE: Compositions and methods for the therapy and diagnosis of colon cancer
INVENTOR(S): King, Gordon E., Shoreline, WA, UNITED STATES
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES
Xu, Jiangchun, Bellevue, WA, UNITED STATES
Secrist, Heather, Seattle, WA, UNITED STATES
Jiang, Yuqiu, Kent, WA, UNITED STATES
PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003166064	A1	20030904
APPLICATION INFO.:	US 2002-99926	A1	20020314 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-33528, filed on 26 Dec 2001, PENDING Continuation-in-part of Ser.		

No. US 2001-920300, filed on 31 Jul 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-302051P	20010629 (60)
	US 2001-279763P	20010328 (60)
	US 2000-223283P	20000803 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
LINE COUNT:	8531	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 5 OF 27 USPATFULL on STN

ACCESSION NUMBER: 2003:106233 USPATFULL

TITLE: Compositions and methods for the therapy and diagnosis of pancreatic cancer

INVENTOR(S): Benson, Darin R., Seattle, WA, UNITED STATES
 Kalos, Michael D., Seattle, WA, UNITED STATES
 Lodes, Michael J., Seattle, WA, UNITED STATES
 Persing, David H., Redmond, WA, UNITED STATES
 Hepler, William T., Seattle, WA, UNITED STATES
 Jiang, Yuqiu, Kent, WA, UNITED STATES

PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003073144	A1	20030417
APPLICATION INFO.:	US 2002-60036	A1	20020130 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-333626P	20011127 (60)
	US 2001-305484P	20010712 (60)
	US 2001-265305P	20010130 (60)
	US 2001-267568P	20010209 (60)
	US 2001-313999P	20010820 (60)
	US 2001-291631P	20010516 (60)
	US 2001-287112P	20010428 (60)
	US 2001-278651P	20010321 (60)
	US 2001-265682P	20010131 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	
NUMBER OF CLAIMS:	17	

EXEMPLARY CLAIM: 1
 LINE COUNT: 14253
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly pancreatic cancer, are disclosed. Illustrative compositions comprise one or more pancreatic tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly pancreatic cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 6 OF 27 PCTFULL COPYRIGHT 2004 Univentio on STN
 ACCESSION NUMBER: 2003103701 PCTFULL ED 20040102 EW 200351
 TITLE (ENGLISH): COMPOSITIONS AND METHODS FOR TREATING DIABETES
 TITLE (FRENCH): COMPOSITIONS ET PROCEDES DE TRAITEMENT DU DIABETE
 INVENTOR(S): BRAND, Stephen, J., 161 Bedford Road, Lincoln, MA 01773, US [AU, US];
 CRUZ, Antonio, 89 Dunloe Road, Toronto, Ontario M5P 2T7, CA [CA, CA]
 PATENT ASSIGNEE(S): WARATAH PHARMACEUTICALS, INC., 415 Yonge Street, Suite 1103, Toronto, Ontario M5B 2E7, CA [CA, CA], for all designates States except US;
 BRAND, Stephen, J., 161 Bedford Road, Lincoln, MA 01773, US [AU, US], for US only;
 CRUZ, Antonio, 89 Dunloe Road, Toronto, Ontario M5P 2T7, CA [CA, CA], for US only
 AGENT: GUTERMAN, Sonia, K.\$, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111\$, US
 LANGUAGE OF FILING: English
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2003103701	A1	20031218

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
 CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
 IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
 MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE
 SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM
 ZW

RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW

RW (EAPO): AM AZ BY KG KZ MD RU TJ TM

RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU
 MC NL PT RO SE SI SK TR

RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2003-US18377 A 20030609

PRIORITY INFO.: US 2002-60/387,032 20020607

US 2002-60/430,590 20021203

ABEN Compositions and methods for islet neogenesis therapy comprising an EGF and a gastrin in combination with immune suppression, and for treating or preventing early stage diabetes with a gastrin/CCK receptor ligand and an immunosuppressant are provided.

ABFR L'invention porte sur des compositions et sur des procedes utilises dans la therapie de la neogenese des ilots pancreatiques, ces compositions

comprenant un EGF et une gastrine en combinaison avec la suppression
immune. Ces procedes consistent a traiter ou prevenir le diabete a un
stade precoce avec un ligand recepteur de gastrine/CCK et un
immunosuppresseur.

L15 ANSWER 7 OF 27 PCTFULL COPYRIGHT 2004 Univentio on STN
ACCESSION NUMBER: 2003100024 PCTFULL ED 20031215 EW 200349
TITLE (ENGLISH): TREATMENT FOR DIABETES
TITLE (FRENCH): TRAITEMENT DU DIABETE
INVENTOR(S): RABINOVITCH, Alex, 148-35 64th Ave, Edmonton, Alberta
T6H 4Y1, CA [CA, CA];
SUAREZ-PINZON, Wilma Lucia, 111-35 83rd Ave, Edmonton,
Alberta T6G 2C6, CA [CO, CA];
CRUZ, Antonio, 89 Dunloe Road, Toronto, Ontario M5P
2T7, CA [CA, CA];
BRAND, Stephen J, 161 Bedford Road, Lincoln, MA 01733,
US [US, AU]
PATENT ASSIGNEE(S): WARATAH PHARMACEUTICALS, INC., 415 Yonge Street, Suite
1103, Toronto, Ontario M5B 2E7, CA [CA, CA], for all
designates States except US;
UNIVERSITY OF ALBERTA, Department of Medicine, 430
Heritage Medical Research Centre, Edmonton, Alberta T6G
2S2, CA [CA, CA], for all designates States except US;
RABINOVITCH, Alex, 148-35 64th Ave, Edmonton, Alberta
T6H 4Y1, CA [CA, CA], for US only;
SUAREZ-PINZON, Wilma Lucia, 111-35 83rd Ave, Edmonton,
Alberta T6G 2C6, CA [CO, CA], for US only;
CRUZ, Antonio, 89 Dunloe Road, Toronto, Ontario M5P
2T7, CA [CA, CA], for US only;
BRAND, Stephen J, 161 Bedford Road, Lincoln, MA 01733,
US [US, AU]
AGENT: RAE-VENTER, Barbara\$, P.O. Box 1898, Monterey, CA
93942\$, US
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2003100024	A2	20031204

DESIGNATED STATES

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE
SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM
ZW

RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU
MC NL PT RO SE SI SK TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2003-US16660 A 20030527
PRIORITY INFO.: US 2002-60/382,921 20020524
US 2002-60/384,357 20020530

ABEN Proliferating pancreatic islet cells obtained by the method of isolating
a population of cells that preferably includes predominantly islet
precursor cells that express one or more marker associated with an islet
precursor cell and providing the precursor cells with one or more a
pancreatic differentiation agent so that a population of cells is

obtained that has a high proportion of cells with phenotypic characteristics of functional pancreatic islet β -cells. Optionally, the precursor cells are pretreated by providing them with one or more cell expansion agent to increase the number of cells in the population prior to differentiation. The pancreatic differentiation agent composition comprises a gastrin/CCK receptor ligand, e.g., a gastrin, in an amount sufficient to effect differentiation of pancreatic islet precursor cells to mature insulin-secreting cells. The cell expansion agent composition comprises one or more epidermal growth factor (EGF) receptor ligand in an amount sufficient to stimulate proliferation of the precursor cells. The methods of treatment include transplanting either undifferentiated precursor cells and providing the pancreatic differentiation agent either alone or in combination with the cell expansion agent in situ, or transplanting the functional pancreatic islet β -cells into the patient. The pancreatic islet β -cells can be used for drug screening, and replenishing pancreatic function in the context of clinical treatment.

ABFR L'invention concerne des cellules des ilots pancréatiques en mitose. Ces cellules sont obtenues par une méthode consistant à isoler une population de cellules qui comprend de préférence des cellules précurseur des ilots pancréatiques qui expriment un ou plusieurs marqueurs associés à une cellule précurseur des ilots pancréatiques. Ces cellules précurseur comprennent un ou plusieurs agents de différenciation pancréatique permettant d'obtenir une population de cellules comportant une proportion de cellules ayant des caractéristiques phénotypiques de cellules β ; des ilots pancréatiques fonctionnelles. Si besoin, les cellules précurseur sont prétraitées en leur administrant un ou plusieurs agents d'expansion afin d'augmenter le nombre de cellules dans la population avant la différenciation. La composition d'agent de différenciation pancréatique comprend un ligand récepteur CCK/gastrine, p. ex., une gastrine, en quantité suffisante pour effectuer une différenciation des cellules précurseur des ilots pancréatiques pour faire murir les cellules qui sécrètent de l'insuline. La composition d'agents d'expansion de cellules comprend un ou plusieurs ligands récepteurs du facteur de croissance épidermique (EGF) en quantité suffisante pour stimuler la prolifération des cellules précurseur. Ces méthodes de traitement consistent à greffer soit les cellules précurseur non différenciées et à libérer des agents de différenciation pancréatique seuls ou en combinaison avec l'agent d'expansion cellulaire in situ, soit à greffer les cellules β ; des ilots pancréatiques chez le patient. Ces cellules β ; des ilots pancréatiques peuvent être utilisées dans le criblage de médicaments et dans la reconstitution de la fonction pancréatique dans le contexte de traitement clinique.

L15 ANSWER 8 OF 27 PCTFULL COPYRIGHT 2004 Univentio on STN
 ACCESSION NUMBER: 2003034980 PCTFULL ED 20030512 EW 200318
 TITLE (ENGLISH): A NOVEL PHARMACEUTICAL COMPOUND CONTAINING ABACAVIR
 SULFATE AND METHODS OF MAKING AND USING SAME
 TITLE (FRENCH): NOUVEAU COMPOSE PHARMACEUTIQUE CONTENANT DU SULFATE
 D'ABACAVIR ET PROCEDES DE FABRICATION ET D'UTILISATION
 ASSOCIES
 INVENTOR(S): PICARIELLO, Thomas, 203 Murphy Street, N.E.,
 Blacksburg, VA 24060, US [US, US]
 PATENT ASSIGNEE(S): NEW RIVER PHARMACEUTICALS INC., The Governor Tyler,
 1902 Downey Street, Radford, VA 24060, US [US, US], for
 all designates States except US;
 PICARIELLO, Thomas, 203 Murphy Street, N.E.,
 Blacksburg, VA 24060, US [US, US]
 AGENT: SCHULMAN, Robert, M.\$, Intellectual Property

Department, Hunton & Williams, 1900 K Street, N.W.,
Suite 1200, Washington, DC 20006-1109\$, US

LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2003034980	A2	20030501

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI
SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

RW (ARIPO):

GH GM KE LS MW MZ SD SL SZ TZ UG ZW

RW (EAPO):

AM AZ BY KG KZ MD RU TJ TM

RW (EPO):

AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
TR

RW (OAPI):

BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.:

WO 2001-US43089 A 20011114

PRIORITY INFO.:

US 2000-60/274,622 20001114

ABEN A composition comprising a polypeptide and benztatropine mesylate covalently attached to the polypeptide. Also provided is a method for delivery of benztatropine mesylate to a patient comprising administering to the patient a composition comprising a polypeptide and benztatropine mesylate covalently attached to the polypeptide. Also provided is a method for protecting benztatropine mesylate from degradation comprising covalently attaching it to a polypeptide. Also provided is a method for controlling release of benztatropine mesylate from a composition comprising covalently attaching it to the polypeptide.

ABFR L'invention concerne une composition comprenant un polypeptide et du benztatropine mesylate relie par covalence au polypeptide. La presente invention concerne egalement un procede d'administration de benztatropine mesylate a un patient, consistant a administrer au patient une composition comprenant un polypeptide et du benztatropine mesylate relie par covalence au polypeptide. En outre, cette invention concerne un procede permettant de proteger le benztatropine mesylate contre la degradation, qui consiste a relier le benztatropine mesylate par covalence a un polypeptide. L'invention concerne egalement un procede de regulation de la liberation de benztatropine mesylate d'une composition, consistant a relier par covalence le benztatropine mesylate au polypeptide.

L15 ANSWER 9 OF 27

PCTFULL COPYRIGHT 2004 Univentio on STN

ACCESSION NUMBER:

2003022987 PCTFULL ED 20030331 EW 200312

TITLE (ENGLISH):

METHODS OF DIAGNOSIS OF HEPATITIS C INFECTION,
COMPOSITIONS AND METHODS OF SCREENING FOR MODULATORS OF
HEPATITIS C INFECTION

TITLE (FRENCH):

PROCEDES DE DIAGNOSTIC DE L'INFECTION PAR L'HEPATITE C,
COMPOSITIONS ET PROCEDES DE CRIBLAGE DE MODULATEURS DE
L'INFECTION PAR L'HEPATITE C

INVENTOR(S):

TOM, Edward, Yat Wah, 864 Shellwood Way, Sacramento, CA
95831, US [US, US];
ZLOTNIK, Albert, 507 Alger Drive, Palo Alto, CA 94306,
US [US, US];
KERSHENOBICH, David, Conjunto Placet, Avenida Club de
Golf Lomas 10, Casa 8, 52788 Huixquilucan, Edo. de
Mexico, MX [MX, MX]

PATENT ASSIGNEE(S):

EOS BIOTECHNOLOGY, INC., 225A Gateway Boulevard, South

San Francisco, CA 94080, US [US, US], for all
 designates States except US;
 TOM, Edward, Yat Wah, 864 Shellwood Way, Sacramento, CA
 95831, US [US, US], for US only;
 ZLOTNIK, Albert, 507 Alger Drive, Palo Alto, CA 94306,
 US [US, US], for US only;
 KERSHENOBICH, David, Conjunto Placet, Avenida Club de
 Golf Lomas 10, Casa 8, 52788 Huixquilucan, Edo. de
 Mexico, MX [MX, MX], for US only
 AGENT: BASTIAN, Kevin, L.\$, Townsend and Townsend and Crew
 LLP, Two Embarcadero Center, Eighth Floor, San
 Francisco, CA 94111-3834\$, US

LANGUAGE OF FILING: English
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2003022987	A2	20030320

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
 CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
 IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
 MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI
 SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

RW (ARIPO):

GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW

RW (EAPO):

AM AZ BY KG KZ MD RU TJ TM

RW (EPO):

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC
 NL PT SE SK TR

RW (OAPI):

BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.:

WO 2002-US23914 A 20020724

PRIORITY INFO.:

US 2001-60/308,188 20010726

US 2002-60/366,782 20020321

ABEN Described herein are genes whose expression are up-regulated or
 down-regulated during the course of Hepatitis C infection, or
 distinction between treatment response. Related methods and compositions
 that can be used for diagnosis and treatment of Hepatitis C infection
 and/or its secondary consequences are disclosed. Also described herein
 are methods that can be used to identify modulators of Hepatitis C
 infection and/or its secondary consequences.

ABFR L'invention concerne des genes dont l'expression est regulee
 positivement ou negativement en cours d'infection par l'hepatite C, ou
 une distinction entre les reponses de traitement. L'invention concerne
 egalement des procedes et des compositions pouvant etre utilises dans le
 diagnostic et le traitement de l'infection par l'hepatite C et/ou ses
 consequences secondaires. L'invention concerne enfin des procedes
 pouvant etre utilises afin d'identifier des modulateurs de l'infection
 par l'hepatite C et/ou ses consequences secondaires.

L15 ANSWER 10 OF 27 USPATFULL on STN

ACCESSION NUMBER: 2002:272801 USPATFULL

TITLE: Compositions and methods for the therapy and diagnosis
 of colon cancer

INVENTOR(S):

Stolk, John A., Bothell, WA, UNITED STATES
 Xu, Jiangchun, Bellevue, WA, UNITED STATES
 Chenault, Ruth A., Seattle, WA, UNITED STATES
 Meagher, Madeleine Joy, Seattle, WA, UNITED STATES

PATENT ASSIGNEE(S):

Corixa Corporation, Seattle, WA, UNITED STATES, 98104
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002150922	A1	20021017
APPLICATION INFO.:	US 2001-998598	A1	20011116 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-304037P	20010710 (60)
	US 2001-279670P	20010328 (60)
	US 2001-267011P	20010206 (60)
	US 2000-252222P	20001120 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
LINE COUNT:	9233	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 11 OF 27 USPATFULL on STN

ACCESSION NUMBER: 2002:243051 USPATFULL

TITLE: Compositions and methods for the therapy and diagnosis of ovarian cancer

INVENTOR(S): Algate, Paul A., Issaquah, WA, UNITED STATES
Jones, Robert, Seattle, WA, UNITED STATES
Harlocker, Susan L., Seattle, WA, UNITED STATES

PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002132237	A1	20020919
APPLICATION INFO.:	US 2001-867701	A1	20010529 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-207484P	20000526 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
LINE COUNT:	25718	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen

presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 12 OF 27 USPATFULL on STN

ACCESSION NUMBER: 2002:185270 USPATFULL

TITLE: Prolonged efficacy of islet neogenesis therapy methods with a gastrin/CCK receptor ligand and an EGF receptor ligand composition in subjects with preexisting diabetes

INVENTOR(S): Brand, Stephen J., Lincoln, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002098178	A1	20020725
APPLICATION INFO.:	US 2002-44048	A1	20020111 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-261638P	20010112 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Sonia K. Guterman, Esq., Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C, One Financial Center, Boston, MA, 02111	
NUMBER OF CLAIMS:	68	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Page(s)	
LINE COUNT:	1032	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods are provided for achieving in vivo islet cell regeneration in subjects with preexisting diabetes. The methods comprise short term treatment with a composition having a gastrin/cholecystokinin receptor ligand and an EGF receptor ligand. Treatment with such a composition for a short term resulted in a prolonged period of increased insulin release, decreased fasting blood glucose, and improved glucose tolerance, the prolonged efficacy, the period being considered from the time of cessation of treatment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 13 OF 27 PCTFULL COPYRIGHT 2004 Univentio on STN

ACCESSION NUMBER: 2002068652 PCTFULL ED 20020916 EW 200236

TITLE (ENGLISH): PROTEINS AND NUCLEIC ACIDS ENCODING SAME

TITLE (FRENCH): PROTEINES ET ACIDES NUCLEIQUES CODANT CES PROTEINES

INVENTOR(S): ALSOBROOK, John, P., II, 60 Lake Drive, Madison, CT 06443, US [US, US];
 ANDERSON, David, W., 555 Long Wharf Drive, 11th floor, New Haven, CT 06511, US [US, US];
 BALLINGER, Robert, A., 25 Starr Avenue, Newington, CT 06111, US [US, US];
 BOLDOG, Ferenc, L., 1687 Hartford Turnpike, North Haven, CT 06473, US [BG, US];
 BURGESS, Catherine, E., 90 Carriage Hill Drive, Wethersfield, CT 06109-4102, US [US, US];
 CASMAN, Stacie, J., 17 Peck Street, North Haven, CT 06473, US [US, US];

ELLERMAN, Karen, E., 87 Montoya Drive, Branford, CT
 06405, US [US, US];
 GANGOLLI, Esha, A., 31 Strawberry Hill Road, Madison,
 CT 06443, US [IN, US];
 GERLACH, Valerie, L., 18 Rock Pasture Road, Branford,
 CT 06405, US [US, US];
 GILBERT, Jennifer, A., 343 Horsepond Road, Madison, CT
 06443, US [US, US];
 GORMAN, Linda, 329 Monticello Drive, Branford, CT
 06405, US [US, US];
 GUO, Xiaojia, 713 Robert Frost Drive, Branford, CT
 06405, US [CN, US];
 GUSEV, Vladimir, Y., 1209 Durham Road, Madison, CT
 06443, US [UA, US];
 KEKUDA, Ramesh, 168 Lockwood Avenue, Stamford, CT
 06902, US [IN, US];
 LI, Li, 56 Jerimoth Drive, Branford, CT 06405, US [CN,
 US];
 LIU, Xiaohong, 96 Montoya Circle, Branford, CT 06405,
 US [CN, US];
 MALYANKAR, Uriel, M., 229 Branford Road, #330,
 Branford, CT 06405, US [IN, US];
 MILLER, Charles, E., 98 Saddle Hill Drive, Guilford, CT
 06437, US [US, US];
 MILLET, Isabelle, 74 Carrington Avenue, Milford, CT
 06460, US [FR, US];
 PADIGARU, Muralidhara, 71 Hampton Park, Branford, CT
 06405, US [IN, US];
 PATTURAJAN, Meera, 45 Harrison Avenue, Apartment 1C,
 Branford, CT 06405, US [IN, US];
 PENA, Carol, E., A., 604 Orange Street, #2, New Haven,
 CT 06511, US [US, US];
 PEYMAN, John, A., 336 West Rock Avenue, New Haven, CT
 06515, US [US, US];
 RASTELLI, Luca, 52 Pepperbush Lane, Guilford, CT 06437,
 US [IT, US];
 SHENOY, Suresh, G., 15 Millwood Drive, Branford, CT
 06405, US [IN, US];
 SHIMKETS, Richard, A., 5 Ludian Meadows Drive,
 Guilford, CT 06437, US [US, US];
 SMITHSON, Glenda, 125 Michael Drive, Guilford, CT
 06435, US [US, US];
 SPYTEK, Kimberly, A., 28 Court Street, #1, New Haven,
 CT 06511, US [US, US];
 STONE, David, J., 223 Whitehorn Drive, Guilford, CT
 06437, US [US, US];
 TAUPIER, Raymond, J., Jr., 34 Pardee Place Extension,
 East Haven, CT 06512, US [US, US];
 TCHERNEV, Velizar, T., 45 Jefferson Road, #3-12,
 Branford, CT 06405, US [BG, US];
 VERNET, Corine, A., M., 1739 Foxon Road, Apartment L6,
 North Branford, CT 06471, US [FR, US];
 ZERHUSEN, Bryan, D., 337 Monticello Drive, Branford, CT
 06405, US [US, US];
 PATENT ASSIGNEE(S): CURAGEN CORPORATION, 555 Long Wharf Drive, 11th floor,
 New Haven, CT 06511, US [US, US], for all designates
 States except US;
 ALSOBROOK, John, P., II, 60 Lake Drive, Madison, CT
 06443, US [US, US], for US only;
 ANDERSON, David, W., 555 Long Wharf Drive, 11th floor,

New Haven, CT 06511, US [US, US], for US only;
 BALLINGER, Robert, A., 25 Starr Avenue, Newington, CT
 06111, US [US, US], for US only;
 BOLDOG, Ferenc, L., 1687 Hartford Turnpike, North
 Haven, CT 06473, US [BG, US], for US only;
 BURGESS, Catherine, E., 90 Carriage Hill Drive,
 Wethersfield, CT 06109-4102, US [US, US], for US only;
 CASMAN, Stacie, J., 17 Peck Street, North Haven, CT
 06473, US [US, US], for US only;
 ELLERMAN, Karen, E., 87 Montoya Drive, Branford, CT
 06405, US [US, US], for US only;
 GANGOLLI, Esha, A., 31 Strawberry Hill Road, Madison,
 CT 06443, US [IN, US], for US only;
 GERLACH, Valerie, L., 18 Rock Pasture Road, Branford,
 CT 06405, US [US, US], for US only;
 GILBERT, Jennifer, A., 343 Horsepond Road, Madison, CT
 06443, US [US, US], for US only;
 GORMAN, Linda, 329 Monticello Drive, Branford, CT
 06405, US [US, US], for US only;
 GUO, Xiaojia, 713 Robert Frost Drive, Branford, CT
 06405, US [CN, US], for US only;
 GUSEV, Vladimir, Y., 1209 Durham Road, Madison, CT
 06443, US [UA, US], for US only;
 KEKUDA, Ramesh, 168 Lockwood Avenue, Stamford, CT
 06902, US [IN, US], for US only;
 LI, Li, 56 Jerimoth Drive, Branford, CT 06405, US [CN,
 US], for US only;
 LIU, Xiaohong, 96 Montoya Circle, Branford, CT 06405,
 US [CN, US], for US only;
 MALYANKAR, Uriel, M., 229 Branford Road, #330,
 Branford, CT 06405, US [IN, US], for US only;
 MILLER, Charles, E., 98 Saddle Hill Drive, Guilford, CT
 06437, US [US, US], for US only;
 MILLET, Isabelle, 74 Carrington Avenue, Milford, CT
 06460, US [FR, US], for US only;
 PADIGARU, Muralidhara, 71 Hampton Park, Branford, CT
 06405, US [IN, US], for US only;
 PATTURAJAN, Meera, 45 Harrison Avenue, Apartment 1C,
 Branford, CT 06405, US [IN, US], for US only;
 PENA, Carol, E., A., 604 Orange Street, #2, New Haven,
 CT 06511, US [US, US], for US only;
 PEYMAN, John, A., 336 West Rock Avenue, New Haven, CT
 06515, US [US, US], for US only;
 RASTELLI, Luca, 52 Pepperbush Lane, Guilford, CT 06437,
 US [IT, US], for US only;
 SHENOY, Suresh, G., 15 Millwood Drive, Branford, CT
 06405, US [IN, US], for US only;
 SHIMKETS, Richard, A., 5 Ludian Meadows Drive,
 Guilford, CT 06437, US [US, US], for US only;
 SMITHSON, Glennda, 125 Michael Drive, Guilford, CT
 06435, US [US, US], for US only;
 SPYTEK, Kimberly, A., 28 Court Street, #1, New Haven,
 CT 06511, US [US, US], for US only;
 STONE, David, J., 223 Whitehorn Drive, Guilford, CT
 06437, US [US, US], for US only;
 TAUPIER, Raymond, J., Jr., 34 Pardee Place Extension,
 East Haven, CT 06512, US [US, US], for US only;
 TCHERNEV, Velizar, T., 45 Jefferson Road, #3-12,
 Branford, CT 06405, US [BG, US], for US only;
 VERNET, Corine, A., M., 1739 Foxon Road, Apartment L6,

North Branford, CT 06471, US [FR, US], for US only;
 ZERHUSEN, Bryan, D., 337 Monticello Drive, Branford, CT
 06405, US [US, US], for US only
 AGENT: ELRIFI, Ivor, R.\$, Mintz, Levin, Cohn, Ferris, Glovsky
 and Popeo, P.C., One Financial Center, Boston, MA
 02111\$, US
 LANGUAGE OF FILING: English
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
--------	------	------

WO 2002068652	A2	20020906
---------------	----	----------

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
 CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
 IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
 MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI
 SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

RW (ARIPO):

GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW

RW (EAPO):

AM AZ BY KG KZ MD RU TJ TM

RW (EPO):

AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
 TR

RW (OAPI):

BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.:

WO 2002-US5910 A 20020226

PRIORITY INFO.:

US 2001-60/271,646 20010226
 US 2001-60/271,840 20010227
 US 2001-60/272,405 20010228
 US 2001-60/272,414 20010228
 US 2001-60/272,404 20010228
 US 2001-60/272,410 20010228
 US 2001-60/273,300 20010302
 US 2001-60/273,048 20010302
 US 2001-60/272,787 20010302
 US 2001-60/272,922 20010302
 US 2001-60/276,401 20010316
 US 2001-60/277,324 20010320
 US 2001-60/278,660 20010320
 US 2001-60/280,234 20010330
 US 2001-60/280,039 20010330
 US 2001-60/280,818 20010402
 US 2001-60/283,443 20010412
 US 2001-60/285,754 20010423
 US 2001-60/286,096 20010424
 US 2001-60/288,353 20010503
 US 2001-60/291,703 20010517
 US 2001-60/294,834 20010531
 US 2001-60/299,695 20010620
 US 2001-60/299,845 20010621
 US 2001-60/303,242 20010705
 US 2001-60/311,981 20010813
 US 2001-60/312,858 20010816
 US 2001-60/313,280 20010817
 US 2001-60/315,614 20010829
 US 2001-60/322,818 20010917
 US 2002-60/322,818 20020225

ABEN Disclosed herein are nucleic acid sequences that encode novel
 polypeptides. Also disclosed are polypeptides encoded by these nucleic
 acid sequences, and antibodies, which immunospecifically-bind to the
 polypeptide, as well as derivatives, variants, mutants, or fragments of

the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

ABFR Cette invention se rapporte a des sequences d'acides nucleiques qui codent de nouveaux polypeptides. Cette invention concerne egalement des polypeptides codes par ces sequences d'acides nucleiques, et des anticorps, qui se fixent de facon immunospecifique a ces polypeptides, ainsi que des derives, des variants, des mutants ou des fragments d'un tel polypeptide, polynucleotide ou anticorps. Cette invention concerne en outre des procedes therapeutiques, diagnostiques et de recherche pour le diagnostic, le traitement et la prevention des affections impliquant l'un de ces nouveaux acides nucleiques et proteines humains.

L15 ANSWER 14 OF 27 PCTFULL COPYRIGHT 2004 Univentio on STN
 ACCESSION NUMBER: 2002055152 PCTFULL ED 20020725 EW 200229
 TITLE (ENGLISH): PROLONGED EFFICACY OF ISLET NEOGENESIS THERAPY METHODS
 WITH A GASTRIN/CCK RECEPTOR LIGAND AND AN EGF RECEPTOR
 LIGAND COMPOSITION IN SUBJECTS WITH PREEXISTING
 DIABETES
 TITLE (FRENCH): EFFICACITE PROLONGEE DE METHODES DE SOINS DE NEOGENESE
 D'ILOT AVEC UNE COMPOSITION DE LIGAND DE RECEPTEUR DE
 GASTRINE/CCK ET DE LIGAND DE RECEPTEUR D'EGF CHEZ DES
 SUJETS A DIABETES PREEXISTANTS
 INVENTOR(S): BRAND, Stephen, J., 161 Bedford Road, Lincoln, MA
 01773, US
 PATENT ASSIGNEE(S): WARATAH PHARMACEUTICALS, INC., 1000 Roessler Road,
 Suite N, Woburn, MA 01801, US [US, CA]
 AGENT: GUTERMAN, Sonia, K.\$, Mintz, Levin, Cohn, Ferris,
 Glovsky and Popeo, P.C., One Financial Center, Boston,
 MA 02111\$, US
 LANGUAGE OF FILING: English
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002055152	A2	20020718

DESIGNATED STATES

W: AU CA JP
 RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
 TR

APPLICATION INFO.: WO 2002-US685 A 20020111
 PRIORITY INFO.: US 2001-60/261,638 20010112

ABEN Compositions and methods are provided for achieving in vivo islet cell regeneration in subjects with preexisting diabetes. The methods comprise short term treatment with a composition having a gastrin/cholecystokinin receptor ligand and an EGF receptor ligand. Treatment with such a composition for a short term resulted in a prolonged period of increased insulin release, decreased fasting blood glucose, and improved glucose tolerance, the prolonged efficacy, the period being considered from the time of cessation of treatment.

ABFR L'invention concerne des compositions et des methodes permettant de realiser une regeneration cellulaire d'ilot <i>in vivo</i> chez des sujets a diabetes preexistants. Les methodes consistent en un traitement court terme avec une composition contenant un ligand de recepteur de gastrine/CCK (cholecystokinine) et un ligand de recepteur d'EGF (facteur de croissance epidermique). Un traitement court terme avec une telle composition resulte en une periode prolongee de liberation amelioree d'insuline, de diminution de la glycemie a jeun, et de tolerance au

glucose amelioree, la duree de l'efficacite prolongee etant comptee a partir de la cessation du traitement.

L15 ANSWER 15 OF 27 PCTFULL COPYRIGHT 2004 Univentio on STN
 ACCESSION NUMBER: 2001057271 PCTFULL ED 20020827
 TITLE (ENGLISH): HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES
 USEFUL FOR ANALYSIS OF GENE EXPRESSION IN HUMAN BREAST
 AND BT 474 CELLS
 TITLE (FRENCH): SONDES D'ACIDE NUCLEIQUE A UN SEUL EXON DERIVEES DU
 GENOME HUMAIN UTILES POUR ANALYSER L'EXPRESSION GENIQUE
 DANS DES CELLULES BT 474
 INVENTOR(S): PENN, Sharron, G.;
 HANZEL, David, K.;
 CHEN, Wensheng;
 RANK, David, R.
 PATENT ASSIGNEE(S): AEROMICA, INC.;
 PENN, Sharron, G.;
 HANZEL, David, K.;
 CHEN, Wensheng;
 RANK, David, R.
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2001057271	A2	20010809

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU
 CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN
 IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK
 MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM
 TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD
 SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY
 DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF
 CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2001-US662 A 20010130
 PRIORITY INFO.: US 2000-60/180,312 20000204
 US 2000-60/207,456 20000526
 US 2000-09/608,408 20000630
 US 2000-09/632,366 20000803
 US 2000-60/234,687 20000921
 US 2000-60/236,359 20000927
 GB 2000-0024263.6 20001004

ABEN A single exon nucleic acid microarray comprising a plurality of single exon nucleic acid probes for measuring gene expression in a sample derived from human BT 474 cells is described. Also described are single exon nucleic acid probes expressed in the BT 474 cells and their use in methods for detecting gene expression.

ABFR Puce a acide nucleique (microarray) a un seul exon comportant une pluralite de sondes d'acide nucleique a un seul exon destinees a mesurer l'expression genique dans un echantillon derive de cellules humaines BT 474. La presente invention concerne egalement des sondes d'acide nucleique a un seul exon exprimees dans les cellules BT 474 et leur utilisation dans des methodes de detection de l'expression genique.

L15 ANSWER 16 OF 27 PCTFULL COPYRIGHT 2004 Univentio on STN
 ACCESSION NUMBER: 2001004311 PCTFULL ED 20020828
 TITLE (ENGLISH): SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
 ACIDS ENCODING THE SAME
 TITLE (FRENCH): POLYPEPTIDES SECRETES ET TRANSMEMBRANAIRES ET ACIDES
 NUCLEIQUES CODANT POUR CES POLYPEPTIDES

INVENTOR(S):

ASHKENAZI, Avi, J.;
 BOTSTEIN, David;
 DESNOYERS, Luc;
 EATON, Dan, L.;
 FERRARA, Napoleone;
 FILVAROFF, Ellen;
 FONG, Sherman;
 GAO, Wei-Qiang;
 GERBER, Hanspeter;
 GERRITSEN, Mary, E.;
 GODDARD, Audrey;
 GODOWSKI, Paul, J.;
 GRIMALDI, Christopher, J.;
 GURNEY, Austin, L.;
 HILLAN, Kenneth, J.;
 KLJAVIN, Ivar, J.;
 MATHER, Jennie, P.;
 PAN, James;
 PAONI, Nicholas, F.;
 ROY, Margaret, Ann;
 STEWART, Timothy, A.;
 TUMAS, Daniel;
 WILLIAMS, P., Mickey;
 WOOD, William, I.

PATENT ASSIGNEE(S):

GENENTECH, INC.;
 ASHKENAZI, Avi, J.;
 BOTSTEIN, David;
 DESNOYERS, Luc;
 EATON, Dan, L.;
 FERRARA, Napoleone;
 FILVAROFF, Ellen;
 FONG, Sherman;
 GAO, Wei-Qiang;
 GERBER, Hanspeter;
 GERRITSEN, Mary, E.;
 GODDARD, Audrey;
 GODOWSKI, Paul, J.;
 GRIMALDI, Christopher, J.;
 GURNEY, Austin, L.;
 HILLAN, Kenneth, J.;
 KLJAVIN, Ivar, J.;
 MATHER, Jennie, P.;
 PAN, James;
 PAONI, Nicholas, F.;
 ROY, Margaret, Ann;
 STEWART, Timothy, A.;
 TUMAS, Daniel;
 WILLIAMS, P., Mickey;
 WOOD, William, I.

DOCUMENT TYPE:

Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2001004311	A1	20010118

DESIGNATED STATES

W:

AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE
 DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE
 KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX
 NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA
 UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW

AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR
GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW
ML MR NE SN TD TG

APPLICATION INFO.: WO 2000-US4414 A 20000222
PRIORITY INFO.: US 1999-60/143,048 19990707
US 1999-60/145,698 19990726
US 1999-60/146,222 19990728
US 1999-PCT/US99/20594 19990908
US 1999-PCT/US99/20944 19990913
US 1999-PCT/US99/21090 19990915
US 1999-PCT/US99/21547 19990915
US 1999-PCT/US99/23089 19991005
US 1999-PCT/US99/28214 19991129
US 1999-PCT/US99/28313 19991130
US 1999-PCT/US99/28564 19991202
US 1999-PCT/US99/28565 19991202
US 1999-PCT/US99/30095 19991216
US 1999-PCT/US99/30911 19991220
US 1999-PCT/US99/30999 19991220
US 2000-PCT/US99/00219 20000105

ABEN The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

ABFR

L15 ANSWER 17 OF 27 PCTFULL COPYRIGHT 2004 Univentio on STN
ACCESSION NUMBER: 2000056882 PCTFULL ED 20020515
TITLE (ENGLISH): 48 HUMAN SECRETED PROTEINS
TITLE (FRENCH): 48 PROTEINES HUMAINES SECRETEES
INVENTOR(S): ROSEN, Craig, A.;
RUBEN, Steven, M.;
KOMATSOULIS, George
PATENT ASSIGNEE(S): HUMAN GENOME SCIENCES, INC.;
ROSEN, Craig, A.;
RUBEN, Steven, M.;
KOMATSOULIS, George
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2000056882	A1	20000928

DESIGNATED STATES
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE
DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE
KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX
NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA
UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW
AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR
GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW
ML MR NE SN TD TG

APPLICATION INFO.: WO 2000-US6791 A 20000316
PRIORITY INFO.: US 1999-60/125,815 19990323
US 1999-60/169,946 19991210

ABEN The present invention relates to 48 novel human secreted proteins and isolated nucleic acids

containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

ABFR L'invention porte sur de nouvelles proteines humaines secretees et sur des acides nucleiques isolees comportant les regions codantes des genes codant pour lesdites proteines. L'invention porte egalement sur des vecteurs, cellules hotes, anticorps, et methodes de recombinaison servant a produire lesdites proteines humaines secretees; elle porte en outre sur des procedes diagnostiques et therapeutiques permettant de diagnostiquer et traiter les affections liees auxdites nouvelles proteines humaines secretees.

L15 ANSWER 18 OF 27 PCTFULL COPYRIGHT 2004 Univentio on STN
 ACCESSION NUMBER: 2000055320 PCTFULL ED 20020515
 TITLE (ENGLISH): HUMAN PANCREAS AND PANCREATIC CANCER ASSOCIATED GENE SEQUENCES AND POLYPEPTIDES
 TITLE (FRENCH): SEQUENCES DE GENES ET POLYPEPTIDES ASSOCIEES AU CANCER DU PANCREAS CHEZ L'HOMME
 INVENTOR(S): ROSEN, Craig, A.; RUBEN, Steven, M.
 PATENT ASSIGNEE(S): HUMAN GENOME SCIENCES, INC.; ROSEN, Craig, A.; RUBEN, Steven, M.
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2000055320	A1	20000921

DESIGNATED STATES

W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2000-US5989 A 20000308

PRIORITY INFO.: US 1999-60/124,270 19990312

ABEN This invention relates to newly identified pancreas or pancreatic cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as pancreatic cancer antigens, and to the complete gene sequences associated therewith and to the expression products thereof, as well as the use of such pancreatic cancer antigens for detection, prevention and treatment of disorders of the pancreas, particularly the presence of pancreatic cancer. This invention relates to the pancreatic cancer antigens as well as vectors, host cells, antibodies directed to pancreatic cancer antigens and recombinant and synthetic methods for

producing the same. Also provided are diagnostic methods for diagnosing and treating, preventing and/or prognosing disorders related to the pancreas, including pancreatic cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of pancreatic cancer antigens of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and/or function of the polypeptides of the present invention.

ABFR L'invention porte sur des polynucleotides et les polypeptides codes par eux nouvellement identifiés connus sous l'appellation collective d'antigenes du cancer du pancreas, sur les sequences completes de genes leur etant associees, sur leurs produits d'expression, ainsi que sur l'utilisation desdits antigenes du cancer du pancreas pour la detection, la prevention et le traitement d'affections du pancreas dont en particulier le cancer du pancreas. L'invention porte sur les antigenes du cancer du pancreas ainsi que sur des vecteurs, des cellules hotes, et des anticorps des antigenes du pancreas, et sur des procedes de recombinaison et de synthese permettant de les produire. L'invention porte egalement sur des methodes de diagnostic permettant de diagnostiquer, traiter, prevenir et/ou pronostiquer les affections du pancreas dont le cancer du pancreas, et sur des procedes therapeutiques permettant de les traiter. L'invention porte en outre sur des procedes de criblage permettant d'identifier les agonistes et antagonistes des antigenes du cancer du pancreas de l'invention, et sur des procedes et/ou compositions inhibant la production et/ou la fonction des polypeptides de l'invention.

L15 ANSWER 19 OF 27 PCTFULL COPYRIGHT 2004 Univentio on STM
 ACCESSION NUMBER: 2000055180 PCTFULL ED 20020515
 TITLE (ENGLISH): HUMAN LUNG CANCER ASSOCIATED GENE SEQUENCES AND
 POLYPEPTIDES
 TITLE (FRENCH): SEQUENCES ET POLYPEPTIDES GENIQUES ASSOCIES AU CANCER
 DU POUMON CHEZ L'HOMME
 INVENTOR(S): RUBEN, Steven, M.
 PATENT ASSIGNEE(S): HUMAN GENOME SCIENCES, INC.;
 ROSEN, Craig, A.;
 RUBEN, Steven, M.
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2000055180	A2	20000921

DESIGNATED STATES

W:

AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
 ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ
 LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO
 RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW
 GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU
 TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL

PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2000-US5918 A 20000308

PRIORITY INFO.: US 1999-60/124,270 19990312

ABEN This invention relates to newly identified lung or lung cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as lung cancer antigens, and to the complete gene sequences associated therewith and to the expression products thereof, as well as the use of such lung cancer antigens for detection, prevention and treatment of disorders of the lung, particularly the presence of lung cancer. This invention relates to the lung cancer antigens as well as vectors, host cells, antibodies directed to lung cancer antigens and recombinant and synthetic methods for producing the same. Also provided are diagnostic methods for diagnosing and treating, preventing and/or prognosing disorders related to the lung, including lung cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of lung cancer antigens of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and/or function of the polypeptides of the present invention.

ABFR Cette invention porte sur des polynucleotides récemment identifiés et associés au cancer du poumon, et sur les polypeptides codés par ces polynucleotides et connus collectivement sous le nom d'antigènes du cancer du poumon. L'invention porte également sur les séquences géniques complètes associées et sur leurs produits d'expression, ainsi que sur l'utilisation de ces antigènes du cancer du poumon dans la détection, la prévention et le traitement des pathologies du poumon telles que le cancer. Cette invention porte sur les antigènes du cancer du poumon, ainsi que sur les vecteurs, les cellules hôtes, les anticorps dirigés contre les antigènes du cancer du poumon et sur des procédés recombinants et synthétiques de production de ces anticorps. L'invention porte également sur des procédés de diagnostic permettant de diagnostiquer et traiter, prévenir et/ou établir un pronostic de pathologies du poumon telles que le cancer, et sur des procédés thérapeutiques visant à traiter ces pathologies. Cette invention porte en outre sur des procédés de recherche automatique visant à identifier des agonistes et des antagonistes des antigènes du cancer du poumon, et sur des procédés et/ou des compositions visant à inhiber la production et/ou la fonction des polypeptides de cette invention.

L15 ANSWER 20 OF 27 PCTFULL COPYRIGHT 2004 Univentio on STN

ACCESSION NUMBER: 2000055173 PCTFULL ED 20020515

TITLE (ENGLISH): HUMAN BREAST AND OVARIAN CANCER ASSOCIATED GENE SEQUENCES AND POLYPEPTIDES

TITLE (FRENCH): SEQUENCES ET POLYPEPTIDES GENIQUES ASSOCIES AU CANCER DES OVAIRES ET DU SEIN

INVENTOR(S): ROSEN, Craig, A.;
 RUBEN, Steven, M.
 PATENT ASSIGNEE(S): HUMAN GENOME SCIENCES, INC.;
 ROSEN, Craig, A.;
 RUBEN, Steven, M.

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2000055173	A1	20000921

DESIGNATED STATES

W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
 ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ
 LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO
 RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW
 GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU
 TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL
 PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2000-US5881 A 20000308

PRIORITY INFO.: US 1999-60/124,270 19990312

ABEN This invention relates to newly identified breast, ovarian, breast cancer and/or ovarian cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as breast/ovarian cancer antigens, and to the complete gene sequences associated therewith and to the expression products thereof, as well as the use of such breast/ovarian cancer antigens for detection, prevention and treatment of disorders of the female reproductive system, particularly disorders of the breast and/or ovary, including the presence of breast cancer and/or ovarian cancer. This invention relates to the breast/ovarian cancer antigens as well as vectors, host cells, antibodies directed to breast/ovarian cancer antigens and recombinant and synthetic methods for producing the same. Also provided are diagnostic methods for diagnosing and treating, preventing and/or prognosing disorders related to the female reproductive system, particularly disorders of the breast and/or ovary, including breast cancer and/or ovarian cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of breast/ovarian cancer antigens of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and/or function of the polypeptides of the present invention.

ABFR Cette invention porte sur des polynucleotides recemment identifies et associes au cancer du sein et/ou des ovaires, et sur les polypeptides codes par ces polynucleotides et connus collectivement sous le nom d'antigenes du cancer du sein/des ovaires. L'invention porte egalement sur les sequences geniques completes associees et sur leurs produits d'expression, ainsi que sur l'utilisation de ces antigenes du cancer du sein/des ovaires dans la detection, la

prevention et le traitement des pathologies du systeme reproducteur
feminin, notamment les
pathologies du sein et/ou des ovaires telles que le cancer. Cette
invention porte sur les antigenes
du cancer du sein/des ovaires ainsi que sur les vecteurs, les cellules
hotes, les anticorps diriges
contre les antigenes et sur des procedes recombinants et synthetiques de
production de ces
anticorps. L'invention porte egalement sur des procedes de diagnostic
permettant de diagnostiquer et
traiter, prevenir et/ou etablir un pronostic de pathologies associees au
systeme reproducteur
feminin, notamment des pathologies du sein et/ou des ovaires telles que
le cancer, et sur des
procedes therapeutiques visant a traiter ces pathologies. Cette
invention porte en outre sur des
procedes de recherche automatique visant a identifier des agonistes et
des antagonistes des
antigenes du cancer du sein/des ovaires, et sur des procedes et/ou des
compositions visant a inhiber
la production et/ou la fonction des polypeptides de cette invention.

L15 ANSWER 21 OF 27 PCTFULL COPYRIGHT 2004 Univentio on STN
ACCESSION NUMBER: 2000017360 PCTFULL ED 20020515
TITLE (ENGLISH): CYSTINE KNOT GROWTH FACTOR MUTANTS
TITLE (FRENCH): MUTANTS DU FACTEUR DE CROISSANCE A NOEUD DE CYSTINE
INVENTOR(S): WEINTRAUB, Bruce, D.;
SZKUDLINSKI, Mariusz, W.
PATENT ASSIGNEE(S): UNIVERSITY OF MARYLAND, BALTIMORE;
WEINTRAUB, Bruce, D.;
SZKUDLINSKI, Mariusz, W.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE

WO 2000017360	A1	20000330

DESIGNATED STATES
W:

AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT
RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU
ZA ZW GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD
RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC
NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 1999-US5908 A 19990319
PRIORITY INFO.: US 1998-PCT/US98/19772 19980922

ABEN Compositions and methods based on mutant Cystine Knot Growth Factors
(CKGFs) comprising amino
acid substitutions relative to the wild type hormone/growth factor.
Mutated glycoprotein hormones,
including thyroid stimulating hormone (TSH) and chorionic gonadotropin
(CG) are disclosed as
exemplary mutant CKGFs. Mutant TSH heterodimers and hCH heterodimers
possessed modified
bioactivities, including superagonist activity. Accordingly, the present
invention provides methods
for using mutant CKGFs CKGF analogs, fragments, and derivatives thereof
for treating or preventing
diseases. Pharmaceutical and diagnostic compositions, methods of using

mutant TSH heterodimers and
TSH analogs with utility for treatment and prevention of metabolic and
reproductive diseases are
also provided.

ABFR Compositions et procedes bases sur des facteurs de croissance a noeud de
cystine (CKGFs)
mutants qui comprennent des substitutions amino-acides par rapport a
l'hormone/facteur de croissance
de type sauvage. Des hormones glycoproteiques mutees, dont la
thyrotrophine (TSH) et la
gonadotropine chorionique (CG) sont presentees en tant que CKGFs
mutantes. Des heterodimeres de TSH
et des heterodimeres de hCH mutants possedent des activites biologiques
modifiees, dont une activite
de superagoniste. La presente invention concerne donc des procedes
d'utilisation de CKGFs mutants,
d'analogues de CKGF, de fragments et de derives desdites substances pour
le traitement ou la
prevention de maladies. Des compositions pharmaceutiques et de
diagnostic, des procedes
d'utilisation d'heterodimeres de TSH et d'analogues de TSH mutants ayant
une utilite pour le
traitement et la prevention de maladies metaboliques et du systeme de
reproduction sont egalement
decrits.

L15 ANSWER 22 OF 27 PCTFULL COPYRIGHT 2004 Univentio on STN
ACCESSION NUMBER: 2000012708 PCTFULL ED 20020515
TITLE (ENGLISH): FURTHER PRO POLYPEPTIDES AND SEQUENCES THEREOF
TITLE (FRENCH): NOUVEAUX PRO-POLYPEPTIDES ET SEQUENCES CORRESPONDANTES
INVENTOR(S): BAKER, Kevin;
GODDARD, Audrey;
GURNEY, Austin, L.;
SMITH, Victoria;
WATANABE, Colin, K.;
WOOD, William, I.
PATENT ASSIGNEE(S): GENENTECH, INC.;
BAKER, Kevin;
GODDARD, Audrey;
GURNEY, Austin, L.;
SMITH, Victoria;
WATANABE, Colin, K.;
WOOD, William, I.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2000012708	A2	20000309

DESIGNATED STATES
W:

AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE
DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG
KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ
PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ
VN YU ZA ZW GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG
KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT
LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN
TD TG

APPLICATION INFO.: WO 1999-US20111 A 19990901
PRIORITY INFO.: US 1998-60/098,716 19980901

US 1998-60/098,749	19980901
US 1998-60/098,750	19980901
US 1998-60/098,803	19980902
US 1998-60/098,821	19980902
US 1998-60/098,843	19980902
US 1998-60/099,536	19980909
US 1998-60/099,596	19980909
US 1998-60/099,598	19980909
US 1998-60/099,602	19980909
US 1998-60/099,642	19980909
US 1998-60/099,741	19980910
US 1998-60/099,754	19980910
US 1998-60/099,763	19980910
US 1998-60/099,792	19980910
US 1998-60/099,808	19980910
US 1998-60/099,812	19980910
US 1998-60/099,815	19980910
US 1998-60/099,816	19980910
US 1998-60/100,385	19980915
US 1998-60/100,388	19980915
US 1998-60/100,390	19980915
US 1998-60/100,584	19980916
US 1998-60/100,627	19980916
US 1998-60/100,661	19980916
US 1998-60/100,662	19980916
US 1998-60/100,664	19980916
US 1998-60/100,683	19980917
US 1998-60/100,684	19980917
US 1998-60/100,710	19980917
US 1998-60/100,711	19980917
US 1998-60/100,919	19980917
US 1998-60/100,930	19980917
US 1998-60/100,848	19980918
US 1998-60/100,849	19980918
US 1998-60/101,014	19980918
US 1998-60/101,068	19980918
US 1998-60/101,071	19980918
US 1998-60/101,279	19980922
US 1998-60/101,471	19980923
US 1998-60/101,472	19980923
US 1998-60/101,474	19980923
US 1998-60/101,475	19980923
US 1998-60/101,476	19980923
US 1998-60/101,477	19980923
US 1998-60/101,479	19980923
US 1998-60/101,738	19980924
US 1998-60/101,741	19980924
US 1998-60/101,743	19980924
US 1998-60/101,915	19980924
US 1998-60/101,916	19980924
US 1998-60/102,207	19980929
US 1998-60/102,240	19980929
US 1998-60/102,307	19980929
US 1998-60/102,330	19980929
US 1998-60/102,331	19980929
US 1998-60/102,484	19980930
US 1998-60/102,487	19980930
US 1998-60/102,570	19980930
US 1998-60/102,571	19980930
US 1998-60/102,684	19981001

US 1998-60/102,687	19981001
US 1998-60/102,965	19981002
US 1998-60/103,258	19981006
US 1998-60/103,449	19981006
US 1998-60/103,314	19981007
US 1998-60/103,315	19981007
US 1998-60/103,328	19981007
US 1998-60/103,395	19981007
US 1998-60/103,396	19981007
US 1998-60/103,401	19981007
US 1998-60/103,633	19981008
US 1998-60/103,678	19981008
US 1998-60/103,679	19981008
US 1998-60/103,711	19981008
US 1998-60/104,257	19981014
US 1998-60/104,987	19981020
US 1998-60/105,000	19981020
US 1998-60/105,002	19981020
US 1998-60/105,104	19981021
US 1998-60/105,169	19981022
US 1998-60/105,266	19981022
US 1998-60/105,693	19981026
US 1998-60/105,694	19981026
US 1998-60/105,807	19981027
US 1998-60/105,881	19981027
US 1998-60/105,882	19981027
US 1998-60/106,062	19981027
US 1998-60/106,023	19981028
US 1998-60/106,029	19981028
US 1998-60/106,030	19981028
US 1998-60/106,032	19981028
US 1998-60/106,033	19981028
US 1998-60/106,178	19981028
US 1998-60/106,248	19981029
US 1998-60/106,384	19981029
US 1998-60/108,500	19981029
US 1998-60/106,464	19981030
US 1998-60/106,856	19981103
US 1998-60/106,902	19981103
US 1998-60/106,905	19981103
US 1998-60/106,919	19981103
US 1998-60/106,932	19981103
US 1998-60/106,934	19981103
US 1998-60/107,783	19981110
US 1998-60/108,775	19981117
US 1998-60/108,779	19981117
US 1998-60/108,787	19981117
US 1998-60/108,788	19981117
US 1998-60/108,801	19981117
US 1998-60/108,802	19981117
US 1998-60/108,806	19981117
US 1998-60/108,807	19981117
US 1998-60/108,867	19981117
US 1998-60/108,925	19981117
US 1998-60/108,848	19981118
US 1998-60/108,849	19981118
US 1998-60/108,850	19981118
US 1998-60/108,851	19981118
US 1998-60/108,852	19981118
US 1998-60/108,858	19981118

US 1998-60/108,904 19981118

ABEN Membrane-bound proteins and receptor molecules have various industrial applications, including as pharmaceutical and diagnostic agents. Receptor immunoadhesins, for instance, can be employed as therapeutic agents to block receptor-ligand interactions. The membrane-bound proteins can also be employed for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction. Efforts are being undertaken by both industry and academia to identify new, native receptor or membrane-bound proteins. Many efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel receptor or membrane-bound proteins. The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

ABFR Les proteines membranaires et les molecules de recepteur possedent differentes applications industrielles ; elles peuvent notamment servir d'agent pharmaceutique et d'agent diagnostique. Les immunoadhesines recepteurs, par exemple, peuvent servir d'agents therapeutiques afin de bloquer les interactions recepteur-ligand. Les proteines membranaires peuvent egalement servir a cribler de potentiels inhibiteurs peptidiques ou inhibiteurs de petites molecules de l'interaction recepteur-ligand pertinente. Des recherches sont menees dans les domaines industriel et universitaire afin d'identifier de nouvelles proteines natives de recepteur ou membranaires. Nombre de ces recherches se concentrent sur le criblage des bibliotheques d'ADN recombinant de mammifere afin d'identifier les sequences de codage pour de nouvelles proteines de recepteur ou membranaires. L'invention concerne de nouveaux polypeptides et des molecules d'acide nucleique codant pour ces polypeptides. L'invention concerne egalement des vecteurs et des cellules hotes contenant lesdites sequences d'acide nucleique, des molecules de polypeptides chimeres contenant les polypeptides selon l'invention fusionnees a des sequences de polypeptides heterologues, des anticorps qui se lient aux polypeptides selon l'invention ainsi que des methodes de production de ces polypeptides.

L15 ANSWER 23 OF 27 PCTFULL COPYRIGHT 2004 Univentio on STN
 ACCESSION NUMBER: 2000006698 PCTFULL ED 20020515
 TITLE (ENGLISH): 98 HUMAN SECRETED PROTEINS
 TITLE (FRENCH): 98 PROTEINES HUMAINES SECRETEES
 INVENTOR(S): KOMATSOU LIS, George, A.;

ROSEN, Craig, A.;
 RUBEN, Steven, M.;
 DUAN, Roxanne;
 MOORE, Paul, A.;
 SHI, Yanggu;
 LAFLEUR, David;
 WEI, Ying-Fei;
 NI, Jian;
 FLORENCE, Kimberly, A.;
 YOUNG, Paul, E.;
 BREWER, Laurie, A.;
 SOPPET, Daniel, R.;
 ENDRESS, Gregory, A.;
 EBNER, Reinhard;
 OLSEN, Henrik, S.;
 MUCENSKI, Michael
 PATENT ASSIGNEE(S): HUMAN GENOME SCIENCES, INC.;
 KOMATSOUKIS, George, A.;
 ROSEN, Craig, A.;
 RUBEN, Steven, M.;
 DUAN, Roxanne;
 MOORE, Paul, A.;
 SHI, Yanggu;
 LAFLEUR, David;
 WEI, Ying-Fei;
 NI, Jian;
 FLORENCE, Kimberly, A.;
 YOUNG, Paul, E.;
 BREWER, Laurie, A.;
 SOPPET, Daniel, R.;
 ENDRESS, Gregory, A.;
 EBNER, Reinhard;
 OLSEN, Henrik, S.;
 MUCENSKI, Michael

LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2000006698	A1	20000210

DESIGNATED STATES

W:

AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
 ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC
 LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU
 SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH
 GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM
 AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
 BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 1999-US17130 A 19990729

PRIORITY INFO.: US 1998-60/094,657 19980730
 US 1998-60/095,486 19980805
 US 1998-60/095,455 19980806
 US 1998-60/095,454 19980806
 US 1998-60/096,319 19980812

ABEN The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention

further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

ABFR La presente invention concerne de nouvelles proteines humaines secretees, ainsi que des acides nucleiques isoles contenant les regions codantes des genes codant pour ces proteines. L'invention concerne egalement des vecteurs, des cellules hotes, des anticorps, et des methodes de recombinaison permettant de produire les proteines humaines secretees. L'invention concerne enfin des methodes diagnostiques et therapeutiques utilisees dans le traitement de troubles associes a ces nouvelles proteines humaines secretees.

L15 ANSWER 24 OF 27 PCTFULL COPYRIGHT 2004 Univentio on STN
 ACCESSION NUMBER: 1999014328 PCTFULL ED 20020515
 TITLE (ENGLISH): SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME
 TITLE (FRENCH): POLYPEPTIDES SECRETES ET TRANSMEMBRANAIRES ET ACIDES NUCLEIQUES LES CODANT
 INVENTOR(S): WOOD, William, I.;
 GURNEY, Austin, L.;
 GODDARD, Audrey;
 PENNICA, Diane;
 CHEN, Jian;
 YUAN, Jean
 PATENT ASSIGNEE(S): GENENTECH, INC.;
 WOOD, William, I.;
 GURNEY, Austin, L.;
 GODDARD, Audrey;
 PENNICA, Diane;
 CHEN, Jian;
 YUAN, Jean
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9914328	A2	19990325

DESIGNATED STATES

W:

AL	AM	AT	AU	AZ	BA	BB	BG	BR	BY	CA	CH	CN	CU	CZ	DE	DK	EE	ES	FI	GB	GE	GH	GM	HR	HU	ID	IL	IS	JP	KE	KG	KP	KR	KZ	LC	LK	LR	LS	LT	LU	LV	MD	MG	MK	MN	MW	MX	NO	NZ	PL	PT	RO	RU	SD	SE	SG	SI	SK	SL	TJ	TM	TR	TT	UA	UG	US	UZ	VN	YU	ZW	GH	GM	KE	LS	MW	SD	SZ	UG	ZW	AM	AZ	BY	KG	KZ	MD	RU	TJ	TM	AT	BE	CH	CY	DE	DK	ES	FI	FR	GB	GR	IE	IT	LU	MC	NL	PT	SE	BF	BJ	CF	CG	CI	CM	GA	GN	GW	ML	MR	NE	SN	TD	TG
----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----

APPLICATION INFO.: WO 1998-US19330 A 19980916

PRIORITY INFO.: US 1997-60/059,115 19970917

US 1997-60/059,184 19970917

US 1997-60/059,122 19970917

US 1997-60/059,117 19970917

US 1997-60/059,113 19970917

US 1997-60/059,121 19970917

US 1997-60/059,119 19970917

US 1997-60/059,263 19970918

US 1997-60/059,266 19970918

US 1997-60/062,125 19971015

US 1997-60/062,287 19971017

US 1997-60/062,285	19971017
US 1997-60/063,486	19971021
US 1997-60/062,816	19971024
US 1997-60/062,814	19971024
US 1997-60/063,127	19971024
US 1997-60/063,120	19971024
US 1997-60/063,121	19971024
US 1997-60/063,045	19971024
US 1997-60/063,128	19971024
US 1997-60/063,329	19971027
US 1997-60/063,327	19971027
US 1997-60/063,549	19971028
US 1997-60/063,541	19971028
US 1997-60/063,550	19971028
US 1997-60/063,542	19971028
US 1997-60/063,544	19971028
US 1997-60/063,564	19971028
US 1997-60/063,734	19971029
US 1997-60/063,738	19971029
US 1997-60/063,704	19971029
US 1997-60/063,435	19971029
US 1997-60/064,215	19971029
US 1997-60/063,735	19971029
US 1997-60/063,732	19971029
US 1997-60/064,103	19971031
US 1997-60/063,870	19971031
US 1997-60/064,248	19971103
US 1997-60/064,809	19971107
US 1997-60/065,186	19971112
US 1997-60/065,846	19971117
US 1997-60/065,693	19971118
US 1997-60/066,120	19971121
US 1997-60/066,364	19971121
US 1997-60/066,772	19971124
US 1997-60/066,466	19971124
US 1997-60/066,770	19971124
US 1997-60/066,511	19971124
US 1997-60/066,453	19971124
US 1997-60/066,840	19971125

ABEN The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptides molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

ABFR La presente invention concerne des polypeptides et des molecules d'acides nucleiques codant ces polypeptides. L'invention concerne egalement des vecteurs et des cellules hotes comprenant ces sequences d'acides nucleiques. L'invention concerne ensuite des molecules de polypeptides chimeriques ou les polypeptides de l'invention sont fusionnes a des sequences de polypeptides heterologues. L'invention concerne aussi des anticorps qui se lient aux polypeptides de l'invention. L'invention concerne enfin des procedes de production des polypeptides

de l'invention.

L15 ANSWER 25 OF 27 PCTFULL COPYRIGHT 2004 Univentio on STN
 ACCESSION NUMBER: 1996023813 PCTFULL ED 20020514
 TITLE (ENGLISH): PEPTIDES AND COMPOUNDS THAT BIND TO SH2 DOMAINS
 TITLE (FRENCH): PEPTIDES ET COMPOSES SE FIXANT AUX DOMAINES SH2
 INVENTOR(S): PATEL, Dinesh, V.;
 GORDEEV, Mikhail, F.;
 GORDON, Eric;
 GROVE, J., Russell;
 HART, Charles, P.;
 KIM, Moon, H.;
 SZARDENINGS, Anna, Katrin

PATENT ASSIGNEE(S): AFFYMAX TECHNOLOGIES N.V.;
 PATEL, Dinesh, V.;
 GORDEEV, Mikhail, F.;
 GORDON, Eric;
 GROVE, J., Russell;
 HART, Charles, P.;
 KIM, Moon, H.;
 SZARDENINGS, Anna, Katrin
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9623813	A1	19960808

DESIGNATED STATES

W:

AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI
 GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG
 MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR
 TT UA UG US UZ VN KE LS MW SD SZ UG AZ BY KG KZ RU TJ
 TM AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF
 BJ CF CG CI CM GA GN ML MR NE SN TD TG

APPLICATION INFO.: WO 1996-US1544 A 19960131
 PRIORITY INFO.: US 1995-8/382,100 19950201
 US 1995-8/382,100 19951220

ABEN The present invention generally relates to peptides and compounds which bind to the SH2 domain or domains of various proteins, as well as methods for identifying such peptides and compounds. These peptides and compounds have application as agonists and antagonists of SH2 domain containing proteins, and as diagnostic or therapeutic agents for the diagnosis or treatment of disease conditions.

ABFR Cette invention traite, d'une maniere generale, de peptides et de composes se fixant au domaine SH2 ou a des domaines de diverses proteines, ainsi que de procedes permettant d'identifier ces peptides et composes. Ceux-ci sont utilises comme agonistes et antagonistes du domaine SH2 contenant des proteines et comme agents diagnostiques et therapeutiques pour le diagnostic ou le traitement d'etats pathologiques.

L15 ANSWER 26 OF 27 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN
 ACCESSION NUMBER: 96:88950 SCISEARCH
 THE GENUINE ARTICLE: TQ251
 TITLE: DISPOSITION KINETICS OF HUMAN EPIDERMAL GROWTH-FACTOR (HEGF1-53) AND ITS TRUNCATED FRAGMENT (HEGF1-48) IN RATS

AUTHOR: KUO B S (Reprint); NORDBLOM G D; DUDECK R C; KIRKISH L S; WRIGHT D S
 CORPORATE SOURCE: WARNER LAMBERT PARKE DAVIS, PHARMACEUT RES DIV, DEPT PHARMACOKINET & DRUG METAB, 2800 PLYMOUTH RD, ANN ARBOR, MI, 48105 (Reprint)
 COUNTRY OF AUTHOR: USA
 SOURCE: DRUG METABOLISM AND DISPOSITION, (JAN 1996) Vol. 24, No. 1, pp. 96-104.
 ISSN: 0090-9556.
 DOCUMENT TYPE: Article; Journal
 FILE SEGMENT: LIFE
 LANGUAGE: ENGLISH
 REFERENCE COUNT: 95

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB Clearance of human epidermal growth factor (hEGF1-53) has been proposed to be mediated by a receptor pathway involving a typical cascade of ligand-receptor endocytosis and lysosomal degradation. **Deletion** of the **C-terminal** pentapeptide from hEGF1-53, which yields hEGF1-48, is known to be associated with a marked reduction in receptor binding. We defined the intravenous (iv)-bolus (acute exposure) and the iv-infusion (prolonged exposure) pharmacokinetics of hEGF1-53 and hEGF1-48 in rats to investigate the impact of the **deletion** of **C-terminal** pentapeptide on the **EGF** clearance using a validated, sensitive ELISA method for quantitation of the peptides in plasma. Both peptides at the low iv bolus dose of 10 μ g/kg were cleared from plasma with unusually high clearances (CL(tot): 128 \pm 31 ml/min/kg for hEGF1-53 and 168 \pm 47 ml/min/kg for hEGF1-48), which are virtually complete within 4-min postdose, and the difference in the overall pharmacokinetics is of minor significance. A 10-fold increase in bolus dose to 100 μ g/kg decreased clearances 3- to 6-fold, indicating a nonlinear kinetics for both peptides; however, hEGF1-48 was cleared (52 \pm 11 ml/min/kg) 2.5-fold faster than hEGF1-53. A similar nonlinear kinetics was also noticed for both peptides when they were **administered** by a 2-hr iv infusion at 30 and 300 μ g/kg doses, hEGF1-48 at the low and high infusion doses was cleared at 126 \pm 16 and 33.7 \pm 14.5 ml/min/kg, respectively, which are 4-fold greater than the corresponding clearance rates of hEGF1-53. These observations suggest that a) **deletion** of **C-terminal** pentapeptide is associated with a faster clearance of the growth factor and b) the receptor clearance pathway may be more sensitive to saturation with hEGF1-53 than with hEGF1-48 at low microgram dose levels, hEGF1-53 at the low infusion dose of 30 μ g/kg was cleared (32.1 \pm 6.2 ml/min/kg) 4-fold slower in comparison with the low bolus dose of 10 μ g/kg, indicating a remarkable injection mode-dependent disposition kinetics for hEGF1-53, which does not exist for hEGF1-48. The overall results suggest that **deletion** of **C-terminal** pentapeptide leads to faster clearance of the growth factor, and the degree of the impact of **deletion** of **C-terminal** pentapeptide on the global pharmacokinetics is also dependent on the length of exposure of the receptor to the ligand. The negative relationship between receptor binding and plasma clearance for the two peptides remains to be elucidated at the molecular and receptor levels.

L15 ANSWER 27 OF 27 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN
 ACCESSION NUMBER: 91:424533 SCISEARCH
 THE GENUINE ARTICLE: FX928
 TITLE: TRANSMEMBRANE SIGNALING AT THE EPIDERMAL GROWTH-FACTOR RECEPTOR - POSITIVE REGULATION BY THE C-TERMINAL PHOSPHOTYROSINE RESIDUES
 AUTHOR: MAGNI M; PANDIELLA A; HELIN K; MELDOLESI J (Reprint);

BEGUINOT L
 CORPORATE SOURCE: UNIV MILAN, SCI INST S RAFFAELE, CNR, CTR CYTOPHARMACOL,
 DEPT PHARMACOL, I-20122 MILAN, ITALY (Reprint); UNIV
 COPENHAGEN, INST MICROBIOL, DK-1168 COPENHAGEN, DENMARK
 COUNTRY OF AUTHOR: ITALY; DENMARK
 SOURCE: BIOCHEMICAL JOURNAL, (1991) Vol. 277, No. JUL, pp. 305-311
 DOCUMENT TYPE: Article; Journal
 FILE SEGMENT: LIFE
 LANGUAGE: ENGLISH
 REFERENCE COUNT: 40

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB Mutant epidermal growth factor (**EGF**) receptors (obtained by substitution of one, two or three C-terminal autophosphorylatable tyrosine residues with phenylalanine residues or by **deletion** of the **C-terminal** 19 amino acids, including the distal tyrosine) were expressed in mouse NIH-3T3 fibroblast clones at densities comparable (< 25 % difference) with those in control clones expressing the wild-type receptor. Total **EGF**-induced phosphorylation of the mutated receptors was not appreciably changed with respect to controls, whereas autophosphorylation at tyrosine residues was decreased, especially in the double and the triple mutants. In the latter mutant, expression of the **EGF**-receptor-activated lipolytic enzyme phospholipase C-gamma was unchanged, whereas its tyrosine phosphorylation induced by the growth factor was lowered to approx. 25 % of that in the controls. In all of the cell clones employed, the accumulation of inositol phosphates induced by **treatment** with fetal calf serum varied only slightly, whereas the same effect induced by **EGF** was consistently lowered in those lines expressing mutated receptors. This decrease was moderate for those receptors missing only the distal tyrosine (point and deletion mutants), intermediate in the dual mutants and almost complete in the triple mutants. Likewise, increases in intracellular Ca^{2+} concentrations ($[Ca^{2+}]_i$) induced by fibroblast growth factor were approximately the same in all of the clones, whereas those induced by **EGF** were decreased in the mutants, again in proportion to the loss of the phosphorylatable C-terminal tyrosine residues. The same trend occurred with membrane hyperpolarization, an effect secondary to the increase in $[Ca^{2+}]_i$ via the activation of Ca^{2+} -dependent K^+ channels. We conclude that C-terminal autophosphorylatable tyrosine residues play a positive role in the regulation of transmembrane signalling at the **EGF** receptor. The stepwise decrease in signal generation observed in single, double and triple point mutants suggest that the role of phosphotyrosine residues is not in the participation in specific amino acid sequences, but rather in the introduction of strong negative charges at strategic sites of the receptor tail. As a consequence of autophosphorylation, the receptor could become competent for specific association with phospholipase C-gamma, with ensuing activation by tyrosine phosphorylation followed by the chains of intracellular responses ultimately leading to DNA synthesis and cell duplication.

=> d his

(FILE 'HOME' ENTERED AT 16:20:37 ON 14 APR 2004)

FILE 'MEDLINE, CAPLUS, SCISEARCH, BIOSIS, USPATFULL, PCTFULL' ENTERED AT 16:21:21 ON 14 APR 2004

L1 364 S GASTRIN(S)DIABETES
 L2 584 S EGF(S)DIABETES
 L3 268 S (ADMINISTER? OR TREAT OR TREATMENT) (S) (L1 OR L2)

L4 32 S L1(S)L2
 L5 257 DUP REM L3 (11 DUPLICATES REMOVED)
 L6 22 DUP REM L4 (10 DUPLICATES REMOVED)
 L7 13 S GASTRIN(S) (LEU OR LEUCINE) (S) ((POSITION? OR RESIDUE OR ACID) (
 L8 12 DUP REM L7 (1 DUPLICATE REMOVED)
 L9 67 S EGF(S) ((DELET?(3W) (C(W) (TERMINUS OR TERMINAL))) OR (NEUTRAL(S
 L10 53 DUP REM L9 (14 DUPLICATES REMOVED)
 L11 2 S L10 AND L2
 L12 6 S L1 AND L7
 L13 27 S (ADMINISTER? OR TREAT OR TREATMENT) (S) (L8 OR L10)
 L14 27 S (ADMINISTER? OR TREAT OR TREATMENT) (S) (L7 OR L9)
 L15 27 DUP REM L14 (0 DUPLICATES REMOVED)
 L16 16 S L5 AND L6

=> s egf(s) (delete or deletion) (s) (two or 2) (s) (c(w) (terminus or terminal))
 5 FILES SEARCHED...

L17 83 EGF(S) (DELETE OR DELETION) (S) (TWO OR 2) (S) (C(W) (TERMINUS OR
 TERMINAL))

=> s egf(s) (delete or deletion) (3w) (two or 2) (s) (c(w) (terminus or terminal))
 5 FILES SEARCHED...

L18 33 EGF(S) (DELETE OR DELETION) (3W) (TWO OR 2) (S) (C(W) (TERMINUS OR
 TERMINAL))

=> dup rem l18

PROCESSING COMPLETED FOR L18

L19 33 DUP REM L18 (0 DUPLICATES REMOVED)

=> s (administer? or treat or treatment) (s) l19
 PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
 FIELD CODE - 'AND' OPERATOR ASSUMED 'TREATMENT) (S) L128'
 PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
 FIELD CODE - 'AND' OPERATOR ASSUMED 'TREATMENT) (S) L130'
 PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
 FIELD CODE - 'AND' OPERATOR ASSUMED 'TREATMENT) (S) L134'
 L20 19 (ADMINISTER? OR TREAT OR TREATMENT) (S) L19

=> d ibib abs 1-19

L20 ANSWER 1 OF 19 USPATFULL on STN

ACCESSION NUMBER: 2004:88520 USPATFULL

TITLE: Therapeutic polypeptides, nucleic acids encoding same,
 and methods of use

INVENTOR(S): Zhong, Mei, Branford, CT, UNITED STATES
 Li, Li, Branford, CT, UNITED STATES
 Gorman, Linda, Branford, CT, UNITED STATES
 Spytek, Kimberly A., New Haven, CT, UNITED STATES
 Kekuda, Ramesh, Norwalk, CT, UNITED STATES
 Taupier, Raymond J., JR., East Haven, CT, UNITED STATES
 Anderson, David W., Branford, CT, UNITED STATES
 Vernet, Corine A.M., Branford, CT, UNITED STATES
 Catterton, Elina, Madison, CT, UNITED STATES
 Miller, Charles E., Guilford, CT, UNITED STATES
 Shenoy, Suresh G., Branford, CT, UNITED STATES
 Patturajan, Meera, Branford, CT, UNITED STATES
 Pena, Carol E. A., New Haven, CT, UNITED STATES
 Tchernev, Velizar T., Branford, CT, UNITED STATES
 Padigar, Muralidhara, Branford, CT, UNITED STATES
 Gusev, Vladimir Y., Madison, CT, UNITED STATES
 Malyankar, Uriel M., Branford, CT, UNITED STATES

Burgess, Catherine E., Wethersfield, CT, UNITED STATES
 Gerlach, Valerie, Branford, CT, UNITED STATES
 Casman, Stacie J., North Haven, CT, UNITED STATES
 Rieger, Daniel K., Branford, CT, UNITED STATES
 Grosse, William M., Branford, CT, UNITED STATES
 Smithson, Glennda, Guilford, CT, UNITED STATES
 Peyman, John A., New Haven, CT, UNITED STATES
 Starling, Gary, Middletown, CT, UNITED STATES
 Rothenberg, Mark E., Clinton, CT, UNITED STATES
 LaRochelle, William J., Madison, CT, UNITED STATES
 Shimkets, Richard A., Guilford, CT, UNITED STATES
 Crabtree, Julie, Gainesville, FL, UNITED STATES
 Rastelli, Luca, Guilford, CT, UNITED STATES
 Voss, Edward Z., Wallingford, CT, UNITED STATES
 Boldog, Ferenc L., North Haven, CT, UNITED STATES
 Edinger, Shlomit R., New Haven, CT, UNITED STATES
 Millet, Isabelle, Milford, CT, UNITED STATES
 MacDougall, John R., Hamden, CT, UNITED STATES
 Ellerman, Karen, Branford, CT, UNITED STATES
 Chapoval, Andrei, Branford, CT, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004067490	A1	20040408	
APPLICATION INFO.:	US 2002-236392	A1	20020906	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-390155P	20020619 (60)
	US 2001-318765P	20010912 (60)
	US 2002-357303P	20020215 (60)
	US 2002-367753P	20020325 (60)
	US 2002-369479P	20020402 (60)
	US 2001-318120P	20010907 (60)
	US 2001-318130P	20010907 (60)
	US 2002-381672P	20020517 (60)
	US 2001-318219P	20010907 (60)
	US 2001-318430P	20010910 (60)
	US 2001-322781P	20010917 (60)
	US 2001-322816P	20010917 (60)
	US 2001-323519P	20010919 (60)
	US 2002-384012P	20020529 (60)
	US 2001-323631P	20010920 (60)
	US 2001-323636P	20010920 (60)
	US 2002-360973P	20020228 (60)
	US 2002-366131P	20020320 (60)
	US 2001-324969P	20010925 (60)
	US 2002-383651P	20020528 (60)
	US 2001-325091P	20010925 (60)
	US 2001-324990P	20010926 (60)
	US 2002-381664P	20020517 (60)
	US 2002-379532P	20020510 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: MINTZ, LEVIN, COHN,, FERRIS, GLOVSKY and POPEO, P.C.,
 One Financial Center, Boston, MA, 02111
 NUMBER OF CLAIMS: 45
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 3 Drawing Page(s)
 LINE COUNT: 36918

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies that immunospecifically bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the novel polypeptide, polynucleotide, or antibody specific to the polypeptide. Vectors, host cells, antibodies and recombinant methods for producing the polypeptides and polynucleotides, as well as methods for using same are also included. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 2 OF 19 USPATFULL on STN

ACCESSION NUMBER: 2004:44501 USPATFULL

TITLE: Proteins and nucleic acids encoding same

INVENTOR(S): Tchernev, Velizar T., Branford, CT, UNITED STATES

Spytek, Kimberly A., New Haven, CT, UNITED STATES

Zerhusen, Bryan D., Branford, CT, UNITED STATES

Patturajan, Meera, Branford, CT, UNITED STATES

Shimkets, Richard A., West Haven, CT, UNITED STATES

Li, Li, Branford, CT, UNITED STATES

Gangolli, Esha A., Madison, CT, UNITED STATES

Padigar, Muralidhara, Branford, CT, UNITED STATES

Anderson, David W., Branford, CT, UNITED STATES

Rastelli, Luca, Guilford, CT, UNITED STATES

Miller, Charles E., Hill Drive, CT, UNITED STATES

Gerlach, Valerie, Branford, CT, UNITED STATES

Taupier, Raymond J., JR., East Haven, CT, UNITED STATES

Gusev, Vladimir Y., UNITED STATES

Colman, Steven D., Guilford, CT, UNITED STATES

Wolenc, Adam Ryan, New Haven, CT, UNITED STATES

Pena, Carol E. A., Guilford, CT, UNITED STATES

Furtak, Katarzyna, Anosia, CT, UNITED STATES

Grosse, William M., Bransford, CT, UNITED STATES

Alsobrook, John P., II, Madison, CT, UNITED STATES

Lepley, Denise M., Branford, CT, UNITED STATES

Rieger, Daniel K., Branford, CT, UNITED STATES

Burgess, Catherine E., Wethersfield, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004033493	A1	20040219
APPLICATION INFO.:	US 2002-72012	A1	20020131 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-267459P	20010208 (60)
	US 2001-266975P	20010207 (60)
	US 2001-267057P	20010207 (60)
	US 2001-266767P	20010205 (60)
	US 2001-266406P	20010202 (60)
	US 2001-265395P	20010131 (60)
	US 2001-265412P	20010131 (60)
	US 2001-265517P	20010131 (60)
	US 2001-265514P	20010131 (60)
	US 2001-267823P	20010209 (60)
	US 2001-268974P	20010215 (60)

US 2001-271855P	20010227 (60)
US 2001-271839P	20010227 (60)
US 2001-273046P	20010302 (60)
US 2001-272788P	20010302 (60)
US 2001-275989P	20010314 (60)
US 2001-275925P	20010314 (60)
US 2001-275947P	20010314 (60)
US 2001-275950P	20010314 (60)
US 2001-276450P	20010315 (60)
US 2001-276448P	20010315 (60)
US 2001-276397P	20010316 (60)
US 2001-276768P	20010316 (60)
US 2001-278652P	20010320 (60)
US 2001-278775P	20010326 (60)
US 2001-278778P	20010326 (60)
US 2001-279882P	20010329 (60)
US 2001-279884P	20010329 (60)
US 2001-280147P	20010330 (60)
US 2001-283083P	20010411 (60)
US 2001-282992P	20010411 (60)
US 2001-285133P	20010420 (60)
US 2001-285749P	20010423 (60)
US 2001-288327P	20010503 (60)
US 2001-288504P	20010503 (60)
US 2001-294047P	20010529 (60)
US 2001-294473P	20010530 (60)
US 2001-296964P	20010608 (60)
US 2001-298959P	20010618 (60)
US 2001-299324P	20010619 (60)
US 2001-312020P	20010813 (60)
US 2001-312908P	20010816 (60)
US 2001-312889P	20010816 (60)
US 2001-313930P	20010821 (60)
US 2001-315470P	20010828 (60)
US 2001-316447P	20010831 (60)
US 2001-318115P	20010907 (60)
US 2001-318118P	20010907 (60)
US 2001-318740P	20010912 (60)
US 2001-323379P	20010919 (60)
US 2001-330308P	20011018 (60)
US 2001-330245P	20011018 (60)
US 2001-332701P	20011114 (60)
US 2001-271664P	20010226 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: Ivor R. Elrifi, Ph.D., Mintz, Levin, Cohn, Ferris,,
 Glovsky and Popeo, P.C., One Financial Center, Boston,
 MA, 02111
 NUMBER OF CLAIMS: 49
 EXEMPLARY CLAIM: 1
 LINE COUNT: 59681
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 10 OF 19 PCTFULL COPYRIGHT 2004 Univentio on STN
 ACCESSION NUMBER: 2003042661 PCTFULL ED 20030530 EW 200321
 TITLE (ENGLISH): METHODS OF DIAGNOSIS OF CANCER, COMPOSITIONS AND
 METHODS OF SCREENING FOR MODULATORS OF CANCER
 TITLE (FRENCH): METHODES DE DIAGNOSTIC DU CANCER, COMPOSITIONS ET
 METHODES DE CRIBLAGE DES MODULATEURS DU CANCER
 INVENTOR(S): AFAR, Daniel, 435 Visitacion Avenue, Brisbane, CA

94005, US [CA, US];
 AZIZ, Natasha, 411 California Avenue, Palo Alto, CA
 94306, US [US, US];
 GINSBURG, Wendy, M., 655 Page Street, San Francisco, CA
 94117, US [US, US];
 GISH, Kurt, C., 37 Artuna Avenue, Piedmont, CA 94611,
 US [US, US];
 GLYNNE, Richard, 2691 Palomino Circle, La Jolla, CA
 92037, US [GB, US];
 HEVEZI, Peter, A., 1360 11th Avenue, San Francisco, CA
 94122, US [GB, US];
 MACK, David, H., 2076 Monterey Avenue, Menlo Park, CA
 94025, US [US, US];
 MURRAY, Richard, 22643 Woodridge Court, Cupertino, CA
 95014, US [US, US];
 WATSON, Susan, R., 805 Balra Drive, El Cerrito, CA
 94530, US [GB, US];
 WILSON, Keith, E., 219 Jeter Street, Redwood City, CA
 94062, US [US, US];
 ZLOTNIK, Albert, 507 Alger Drive, Palo Alto, CA 94306,
 US [US, US]

PATENT ASSIGNEE(S):

EOS BIOTECHNOLOGY, INC., 225A Gateway Boulevard, South
 San Francisco, CA 94080, US [US, US], for all
 designates States except US;
 AFAR, Daniel, 435 Visitacion Avenue, Brisbane, CA
 94005, US [CA, US], for US only;
 AZIZ, Natasha, 411 California Avenue, Palo Alto, CA
 94306, US [US, US], for US only;
 GINSBURG, Wendy, M., 655 Page Street, San Francisco, CA
 94117, US [US, US], for US only;
 GISH, Kurt, C., 37 Artuna Avenue, Piedmont, CA 94611,
 US [US, US], for US only;
 GLYNNE, Richard, 2691 Palomino Circle, La Jolla, CA
 92037, US [GB, US], for US only;
 HEVEZI, Peter, A., 1360 11th Avenue, San Francisco, CA
 94122, US [GB, US], for US only;
 MACK, David, H., 2076 Monterey Avenue, Menlo Park, CA
 94025, US [US, US], for US only;
 MURRAY, Richard, 22643 Woodridge Court, Cupertino, CA
 95014, US [US, US], for US only;
 WATSON, Susan, R., 805 Balra Drive, El Cerrito, CA
 94530, US [GB, US], for US only;
 WILSON, Keith, E., 219 Jeter Street, Redwood City, CA
 94062, US [US, US], for US only;
 ZLOTNIK, Albert, 507 Alger Drive, Palo Alto, CA 94306,
 US [US, US], for US only

AGENT:

BASTIAN, Kevin, L.\$, Townsend and Townsend and Crew
 LLP, Two Embarcadero Center, Eighth Floor, San
 Francisco, CA 94111\$, US

LANGUAGE OF FILING:

English

LANGUAGE OF PUBL.:

English

DOCUMENT TYPE:

Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2003042661	A2	20030522

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
 CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
 IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD

MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG
SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM
ZW

RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC
NL PT SE SK TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2002-US36810 A 20021113
PRIORITY INFO.: US 2001-60/350,666 20011113
US 2001-60/332,464 20011121
US 2001-60/334,393 20011129
US 2001-60/335,394 20011203
US 2001-60/340,376 20011214
US 2002-60/347,211 20020108
US 2002-60/347,349 20020110
US 2002-60/347,349 20020208
US 2002-60/356,714 20020213
US 2002-60/359,077 20020220
US 2002-60/368,809 20020329
US 2002-60/370,110 20020404
US 2002-60/372,246 20020412
US 2002-60/386,614 20020605
US 2002-60/396,839 20020716
US 2002-60/397,775 20020722
US 2002-60/397,845 20020722
US 2002-60/409,450 20020909

ABEN Described herein are genes whose expression are up-regulated or down-regulated in specific cancers or other diseases, or are otherwise regulated in disease. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of these selected conditions.

ABFR Cette invention concerne des genes dont l'expression est regulee positivement ou negativement dans certains cancers ou pathologies specifiques, ou bien dont l'expression est regulee dans les etats pathologiques. Sont egalement decrites des methodes et des compositions connexes convenant pour le diagnostic, le pronostic et le traitement de ces pathologie ainsi que ces methodes permettant d'identifier les modulateurs de ces dernieres.

L20 ANSWER 11 OF 19 PCTFULL COPYRIGHT 2004 Univentio on STN
ACCESSION NUMBER: 2003033515 PCTFULL ED 20030430 EW 200317
TITLE (ENGLISH): COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF ACNE VULGARIS
TITLE (FRENCH): COMPOSITIONS ET METHODES POUR LE TRAITEMENT ET LE DIAGNOSTIC DE L'ACNE VULGAIRE
INVENTOR(S): MITCHAM, Jennifer, L., 16677 Ne 88th Street, Redmond, WA 98052, US [US, US];
SKEIKY, Yasir, A., W., 15106 Southeast 47th Place, Bellevue, WA 98006, US [LB, US];
PERSING, David, H., 22401 N.E. 25th Way, Redmond, WA 98053, US [US, US];
BHATIA, Ajay, 1705 Summit Avenue, #103, Seattle, WA 98122, US [IN, US];
MAISONNEUVE, Jean-Francois, L., 7401 Fauntleroy Way Southwest, #304, Seattle, WA 98136, US [BE, US];
ZHANG, Yanni, 4747 Sandpoint Way, N.E., #302, Seattle, WA 98105, US [CA, US];
WANG, Siqing, 10145 224th Avenue Northeast, Redmond, WA

98053, US [US, US];
 JEN, Shyian, 2345-1/2 Boylston Ave. E. #201, Seattle,
 WA 98122, US [US, US];
 LODES, Michael, J., 9223 - 36th Avenue Southwest,
 Seattle, Washington 98126, US [US, US];
 BENSON, Darin, R., 723 N. 48th Street, Seattle, WA
 98103, US [US, US];
 JONES, Robert, 900 20th Avenue E., Seattle, WA 98112,
 US [GB, US];
 CARTER, Darrick, 321 Summit Ave. E., Seattle, WA 98102,
 US [US, US];
 BARTH, Brenda, 3303 31st Avenue S.W., Seattle, WA
 98126, US [US, US];
 VALLIEVE-DOUGLASS, John, 1132 N.W. 63rd Street,
 Seattle, WA 98107, US [US, US]
 PATENT ASSIGNEE(S): CORIXA CORPORATION, 1124 Columbia Street, Suite 200,
 Seattle, WA 98104, US [US, US], for all designates
 States except US;
 MITCHAM, Jennifer, L., 16677 Ne 88th Street, Redmond,
 WA 98052, US [US, US], for US only;
 SKEIKY, Yasir, A., W., 15106 Southeast 47th Place,
 Bellevue, WA 98006, US [LB, US], for US only;
 PERSING, David, H., 22401 N.E. 25th Way, Redmond, WA
 98053, US [US, US], for US only;
 BHATIA, Ajay, 1705 Summit Avenue, #103, Seattle, WA
 98122, US [IN, US], for US only;
 MAISONNEUVE, Jean-Francois, L., 7401 Fauntleroy Way
 Southwest, #304, Seattle, WA 98136, US [BE, US], for US
 only;
 ZHANG, Yanni, 4747 Sandpoint Way, N.E., #302, Seattle,
 WA 98105, US [CA, US], for US only;
 WANG, Siqing, 10145 224th Avenue Northeast, Redmond, WA
 98053, US [US, US], for US only;
 JEN, Shyian, 2345-1/2 Boylston Ave. E. #201, Seattle,
 WA 98122, US [US, US], for US only;
 LODES, Michael, J., 9223 - 36th Avenue Southwest,
 Seattle, Washington 98126, US [US, US], for US only;
 BENSON, Darin, R., 723 N. 48th Street, Seattle, WA
 98103, US [US, US], for US only;
 JONES, Robert, 900 20th Avenue E., Seattle, WA 98112,
 US [GB, US], for US only;
 CARTER, Darrick, 321 Summit Ave. E., Seattle, WA 98102,
 US [US, US], for US only;
 BARTH, Brenda, 3303 31st Avenue S.W., Seattle, WA
 98126, US [US, US], for US only;
 VALLIEVE-DOUGLASS, John, 1132 N.W. 63rd Street,
 Seattle, WA 98107, US [US, US], for US only
 AGENT: LINGENFELTER, Susan, L.\$, Corixa Corporation, 1124
 Columbia Street, Suite 200, Seattle, WA 98104\$, US

LANGUAGE OF FILING:
 English
 LANGUAGE OF PUBL.:
 English
 DOCUMENT TYPE:
 Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2003033515	A1	20030424

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
 CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
 IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD

MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL
TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC
NL PT SE SK TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
APPLICATION INFO.: WO 2002-US32727 A 20021011
PRIORITY INFO.: US 2001-09/978,825 20011015

ABEN Compositions and methods for the therapy and diagnosis of acne vulgaris and other related conditions are disclosed. Compositions may comprise one or more <i>Propionibacterium acnes</i> proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antibody that binds a <i>Propionibacterium acnes</i> protein, antigen presenting cell that expresses a <i>Propionibacterium acnes</i> protein, or a T cell that is specific for cells expressing such a protein. Such compositions may be used, for example, for the prevention and/or treatment of acne.

ABFR L'invention concerne des compositions et des methodes destinees au traitement et au diagnostic de l'acne vulgaire et d'autres affections associees. Ces compositions peuvent comprendre une ou plusieurs proteines de <i>Propionibacterium acnes</i>, des parties immunogenes correspondantes, ou des polynucleotides codant pour ces parties. Dans un autre mode de realisation, une composition therapeutique peut comprendre un anticorps se liant a une proteine de <i>Propionibacterium acnes</i>, une cellule presentatrice d'antigene exprimant une proteine de <i>Propionibacterium acnes</i>, ou un lymphocyte T specifique pour les cellules exprimant cette proteine. Lesdites compositions peuvent etre utilisees, par exemple, dans la prevention et/ou le traitement de l'acne.

L20 ANSWER 12 OF 19 PCTFULL COPYRIGHT 2004 Univentio on STN
ACCESSION NUMBER: 2003025138 PCTFULL ED 20030402 EW 200313
TITLE (ENGLISH): METHODS OF DIAGNOSIS OF CANCER COMPOSITIONS AND METHODS OF SCREENING FOR MODULATORS OF CANCER
TITLE (FRENCH): PROCEDES DE DIAGNOSTIC DU CANCER, COMPOSITIONS ET PROCEDES DE CRIBLAGE DE MODULATEURS DU CANCER
INVENTOR(S): AFAR, Daniel, 435 Visitacion Avenue, Brisbane, CA 94005, US [CA, US];
AZIZ, Natasha, 411 California Avenue, Palo Alto, CA 94306, US [US, US];
GISH, Kurt, C., 37 Artuna Avenue, Piedmont, CA 94611, US [US, US];
HEVEZI, Peter, A., 1360 11th Avenue, San Francisco, CA 94122, US [GB, US];
MACK, David, H., 2076 Monterey Avenue, Menlo Park, CA 94025, US [US, US];
WILSON, Keith, E., 219 Jeter Street, Redwood City, CA 94062, US [US, US];
ZLOTNIK, Albert, 507 Alger Drive, Palo Alto, CA 94306, US [US, US]
PATENT ASSIGNEE(S): EOS BIOTECHNOLOGY, INC., 225A Gateway, Boulevard, South San Francisco, CA 94080, US [US, US], for all designates States except US;
AFAR, Daniel, 435 Visitacion Avenue, Brisbane, CA 94005, US [CA, US], for US only;
AZIZ, Natasha, 411 California Avenue, Palo Alto, CA 94306, US [US, US], for US only;
GISH, Kurt, C., 37 Artuna Avenue, Piedmont, CA 94611, US [US, US], for US only;

HEVEZI, Peter, A., 1360 11th Avenue, San Francisco, CA 94122, US [GB, US], for US only;
 MACK, David, H., 2076 Monterey Avenue, Menlo Park, CA 94025, US [US, US], for US only;
 WILSON, Keith, E., 219 Jeter Street, Redwood City, CA 94062, US [US, US], for US only;
 ZLOTNIK, Albert, 507 Alger Drive, Palo Alto, CA 94306, US [US, US], for US only
 AGENT: BASTIAN, Kevin, L.\$, Townsend and Townsend and Crew LLP, Two Embarcadero Center, Eighth Floor, San Francisco, CA 94111\$, US
 LANGUAGE OF FILING: English
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2003025138	A2	20030327

DESIGNATED STATES

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR .
 CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
 IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
 MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI
 SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
 RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
 RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC
 NL PT SE SK TR
 RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2002-US29560 A 20020917
 PRIORITY INFO.: US 2001-60/323,469 20010917
 US 2001-60/323,887 20010920
 US 2001-60/350,666 20011113
 US 2002-60/355,145 20020208
 US 2002-60/355,257 20020208
 US 2002-60/372,246 20020412

ABEN Described herein are genes whose expression are up-regulated or down-regulated in specific cancers. Related methods and compositions that can be used for diagnosis and treatment of those cancers are disclosed. Also described herein are methods that can be used to identify modulators of selected cancers.

ABFR L'invention concerne des genes dont l'expression est regulee positivement ou negativement dans des cancers specifiques ; des procedes et des compositions associees pouvant servir a diagnostiquer et a traiter ces cancers ; et des procedes pouvant servir a identifier des modulateurs de cancers selectionnes.

L20 ANSWER 13 OF 19 PCTFULL COPYRIGHT 2004 Univentio on STN
 ACCESSION NUMBER: 2002057304 PCTFULL ED 20020801 EW 200230
 TITLE (ENGLISH): SECRETORY MOLECULES
 TITLE (FRENCH): MOLECULES SECRETRICES
 INVENTOR(S): PANZER, Scott, R., 571 Bobolink Circle, Sunnyvale, CA 94087, US [US, US];
 LINCOLN, Stephen, E., 10637 Rock Run Drive, Potomac, MD 20854, US [US, US];
 ALTUS, Christina, M., 625 Virginia Avenue, Campbell, CA 95008, US [US, US];
 DUFOUR, Gerard, E., 5327 Greenridge Road, Castro Valley, CA 94552, US [US, US];
 HILLMAN, Jennifer, L., 230 Monrow Drive, #17, Mountain

View, CA 94040, US [US, US];
 JONES, Anissa, Lee, 445 South 15th Street, San Jose, CA 95112, US [US, US];
 DAM, Tam, C., 2180 Mendota Way, San Jose, CA 95122, US [US, US];
 LIU, Tommy, F., 201 Ottilia Street, Daly City, Ca 94014, US [US, US];
 HARRIS, Bernard, 1014 Lupine Drive, Sunnyvale, CA 94086, US [US, US];
 FLORES, Vincent, 35000 Begonia Street, Union City, CA 94587, US [US, US];
 DAFFO, Abel, 1750 Stokes Street #70, San Jose, CA 95126, US [US, US];
 MARWAHA, Rakesh, 16272 Saratoga Street, #4, San Leandro, CA 94578, US [US, US];
 CHEN, Alice, J., 4405 Norwalk Drive, #22, San Jose, CA 95129, US [US, US];
 CHANG, Simon, C., 1901 Rock Street #103, Mountain View, CA 94043, US [US, US];
 GERSTIN, Edward, H., Jr., 1408 38th Avenue, San Francisco, CA 94122, US [US, US];
 PERALTA, Careyna, H., 4585 Lakeshore Drive, Santa Clara, CA 95054, US [US, US];
 DAVID, Marie, H., 131 Mirada Drive, Daly City, CA 94015, US [US, US];
 LEWIS, Samantha, A., 1476-148th Avenue, San Leandro, CA 94578, US [US, US];
 PATENT ASSIGNEE(S): INCYTE GENOMICS, INC., 3160 Porter Drive, Palo Alto, CA 94304, US [US, US], for all designates States except US;
 PANZER, Scott, R., 571 Bobolink Circle, Sunnyvale, CA 94087, US [US, US], for US only;
 LINCOLN, Stephen, E., 10637 Rock Run Drive, Potomac, MD 20854, US [US, US], for US only;
 ALTUS, Christina, M., 625 Virginia Avenue, Campbell, CA 95008, US [US, US], for US only;
 DUFOUR, Gerard, E., 5327 Greenridge Road, Castro Valley, CA 94552, US [US, US], for US only;
 HILLMAN, Jennifer, L., 230 Monrow Drive, #17, Mountain View, CA 94040, US [US, US], for US only;
 JONES, Anissa, Lee, 445 South 15th Street, San Jose, CA 95112, US [US, US], for US only;
 DAM, Tam, C., 2180 Mendota Way, San Jose, CA 95122, US [US, US], for US only;
 LIU, Tommy, F., 201 Ottilia Street, Daly City, Ca 94014, US [US, US], for US only;
 HARRIS, Bernard, 1014 Lupine Drive, Sunnyvale, CA 94086, US [US, US], for US only;
 FLORES, Vincent, 35000 Begonia Street, Union City, CA 94587, US [US, US], for US only;
 DAFFO, Abel, 1750 Stokes Street #70, San Jose, CA 95126, US [US, US], for US only;
 MARWAHA, Rakesh, 16272 Saratoga Street, #4, San Leandro, CA 94578, US [US, US], for US only;
 CHEN, Alice, J., 4405 Norwalk Drive, #22, San Jose, CA 95129, US [US, US], for US only;
 CHANG, Simon, C., 1901 Rock Street #103, Mountain View, CA 94043, US [US, US], for US only;
 GERSTIN, Edward, H., Jr., 1408 38th Avenue, San Francisco, CA 94122, US [US, US], for US only;

PERALTA, Careyna, H., 4585 Lakeshore Drive, Santa Clara, CA 95054, US [US, US], for US only;
 DAVID, Marie, H., 131 Mirada Drive, Daly City, CA 94015, US [US, US], for US only;
 LEWIS, Samantha, A., 1476-148th Avenue, San Leandro, CA 94578, US [US, US], for US only
 AGENT: HAMLET-COX, Diana\$, Incyte Genomics, Inc., 3160 Porter Drive, Palo Alto, CA 94304\$, US
 LANGUAGE OF FILING: English
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002057304	A2	20020725

DESIGNATED STATES

W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM

RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW

RW (EAPO): AM AZ BY KG KZ MD RU TJ TM

RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2002-US1340 A 20020115

PRIORITY INFO.: US 2001-60/261,865 20010116
 US 2001-60/261,979 20010116
 US 2001-60/261,864 20010116
 US 2001-60/261,981 20010116
 US 2001-60/263,131 20010117
 US 2001-60/262,208 20010117
 US 2001-60/262,164 20010117
 US 2001-60/262,599 20010119
 US 2001-60/263,329 20010119
 US 2001-60/263,131 20010119
 US 2001-60/263,063 20010119
 US 2001-60/262,760 20010119
 US 2001-60/263,070 20010119
 US 2001-60/263,066 20010119
 US 2001-60/263,077 20010119
 US 2001-60/263/076 20010119
 US 2001-60/263/074 20010119
 US 2001-60/263/069 20010119

ABEN The present invention provides purified secretory polynucleotides (sptm). Also encompassed are the polypeptides (SPTM) encoded by sptm. The invention also provides for the use of sptm, or complements, oligonucleotides, or fragments thereof in diagnostic assays. The invention further provides for vectors and host cells containing sptm for the expression of SPTM. The invention additionally provides for the use of isolated and purified SPTM to induce antibodies and to screen libraries of compounds and the use of anti-SPTM antibodies in diagnostic assays. Also provided are microarrays containing sptm and methods of use.

ABFR L'invention concerne des polynucleotides secretrices purifiees (sptm). L'invention concerne egalement des polypeptides (SPTM) codes par les sptm. L'invention regarde l'utilisation des sptm ou de complements, d'oligonucleotides ou de fragments de ceux-ci dans des dosages biologiques de diagnostic. L'invention concerne egalement des vecteurs

et des cellules hotes contenant des sptm pour l'expression des SPTM.
L'invention decrit aussi l'utilisation de SPTM purifiees et isolees afin
de produire des anticorps et de depister des bibliotheques de composants
et l'utilisation d'anticorps anti-SPTM dans des dosages biologiques de
diagnostic. L'invention concerne enfin des jeux ordonnes d'echantillons
contenant des sptm et des procedes d'utilisation.

L20 ANSWER 14 OF 19 PCTFULL COPYRIGHT 2004 Univentio on STN
ACCESSION NUMBER: 2002055152 PCTFULL ED 20020725 EW 200229
TITLE (ENGLISH): PROLONGED EFFICACY OF ISLET NEOGENESIS THERAPY METHODS
WITH A GASTRIN/CCK RECEPTOR LIGAND AND AN EGF RECEPTOR
LIGAND COMPOSITION IN SUBJECTS WITH PREEXISTING
DIABETES
TITLE (FRENCH): EFFICACITE PROLONGEE DE METHODES DE SOINS DE NEOGENESE
D'ILLOT AVEC UNE COMPOSITION DE LIGAND DE RECEPTEUR DE
GASTRINE/CCK ET DE LIGAND DE RECEPTEUR D'EGF CHEZ DES
SUJETS A DIABETES PREEXISTANTS
INVENTOR(S): BRAND, Stephen, J., 161 Bedford Road, Lincoln, MA
01773, US
PATENT ASSIGNEE(S): WARATAH PHARMACEUTICALS, INC., 1000 Roessler Road,
Suite N, Woburn, MA 01801, US [US, CA]
AGENT: GUTERMAN, Sonia, K.\$, Mintz, Levin, Cohn, Ferris,
Glovsky and Popeo, P.C., One Financial Center, Boston,
MA 02111\$, US
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002055152	A2	20020718

DESIGNATED STATES

W: AU CA JP
RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
TR

APPLICATION INFO.: WO 2002-US685 A 20020111
PRIORITY INFO.: US 2001-60/261,638 20010112

ABEN Compositions and methods are provided for achieving in vivo islet cell
regeneration in subjects with preexisting diabetes. The methods comprise
short term treatment with a composition having a gastrin/cholecystokinin
receptor ligand and an EGF receptor ligand. Treatment with such a
composition for a short term resulted in a prolonged period of increased
insulin release, decreased fasting blood glucose, and improved glucose
tolerance, the prolonged efficacy, the period being considered from the
time of cessation of treatment.

ABFR L'invention concerne des compositions et des methodes permettant de
realiser une regeneration cellulaire d'ilot <i>in vivo</i> chez des
sujets a diabetes preexistants. Les methodes consistent en un traitement
court terme avec une composition contenant un ligand de recepteur de
gastrine/CCK (cholecystokinine) et un ligand de recepteur d'EGF (facteur
de croissance epidermique). Un traitement court terme avec une telle
composition resulte en une periode prolongee de liberation amelioree
d'insuline, de diminution de la glycemie a jeun, et de tolerance au
glucose amelioree, la duree de l'efficacite prolongee etant comptee a
partir de la cessation du traitement.

L20 ANSWER 15 OF 19 PCTFULL COPYRIGHT 2004 Univentio on STN
ACCESSION NUMBER: 2001081581 PCTFULL ED 20020826
TITLE (ENGLISH): COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS
OF ACNE VULGARIS

TITLE (FRENCH): COMPOSITIONS ET PROCEDES POUR LA THERAPIE ET LE
 DIAGNOSTIC DE L'ACNE VULGAIRE
 INVENTOR(S): SKEIKY, Yasir, A., W.;
 PERSING, David, H.;
 MITCHAM, Jennifer, L.;
 WANG, Siqing, Steven;
 BHATIA, Ajay;
 L'MAISONNEUVE, Jean-Francois;
 ZHANG, Yanni;
 JEN, Shyian;
 CARTER, Darrick
 PATENT ASSIGNEE(S): CORIXA CORPORATION;
 SKEIKY, Yasir, A., W.;
 PERSING, David, H.;
 MITCHAM, Jennifer, L.;
 WANG, Siqing, Steven;
 BHATIA, Ajay;
 L'MAISONNEUVE, Jean-Francois;
 ZHANG, Yanni;
 JEN, Shyian;
 CARTER, Darrick
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2001081581	A2	20011101

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
 CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL
 IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG
 MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ
 TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ
 SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH
 CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ
 CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2001-US12865 A 20010420
 PRIORITY INFO.: US 2000-60/199,047 20000421
 US 2000-60/208,841 20000602
 US 2000-60/216,747 20000707

ABEN Compositions and methods for the therapy and diagnosis of acne vulgaris and other related conditions are disclosed. Compositions may comprise one or more <i>Propionibacterium acnes</i> proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antibody that binds a <i>Propionibacterium acnes</i> protein, antigen presenting cell that expresses a <i>Propionibacterium acnes</i> protein, or a T cell that is specific for cells expressing such a protein. Such compositions may be used, for example, for the prevention and/or treatment of acne.

ABFR L'invention concerne les compositions et les procedes pour la therapie et le diagnostic de l'acne vulgaire et d'autres etats apparentes. Les compositions peuvent comprendre une ou plusieurs proteines de <i>Propionibacterium acnes</i>, des fractions immunogenes de celles-ci, ou des polynucleotides qui codent de telles fractions. Selon une variante, une composition therapeutique peut comprendre un anticorps qui fixe une proteine de <i>Propionibacterium acnes</i>, une cellule presentant un antigene qui exprime une proteine de <i>Propionibacterium acnes</i>, ou une cellule T qui agit specifiquement sur les cellules exprimant une telle proteine. De telles compositions peuvent etre utilisees, par exemple, pour la prevention et/ou le traitement de l'acne.

L20 ANSWER 16 OF 19 PCTFULL COPYRIGHT 2004 Univentio on STN
 ACCESSION NUMBER: 2001057277 PCTFULL ED 20020827
 TITLE (ENGLISH): HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES
 USEFUL FOR ANALYSIS OF GENE EXPRESSION IN HUMAN FETAL
 LIVER
 TITLE (FRENCH): SONDAS D'ACIDE NUCLEIQUE A UN SEUL EXON DERIVEES DU
 GENOME HUMAIN UTILES POUR ANALYSER L'EXPRESSION GENIQUE
 DANS LE FOIE FOETAL HUMAIN
 INVENTOR(S): PENN, Sharron, G.;
 HANZEL, David, K.;
 CHEN, Wensheng;
 RANK, David, R.
 PATENT ASSIGNEE(S): MOLECULAR DYNAMICS, INC.;
 PENN, Sharron, G.;
 HANZEL, David, K.;
 CHEN, Wensheng;
 RANK, David, R.
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2001057277	A2	20010809

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU
 CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN
 IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK
 MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM
 TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD
 SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY
 DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF
 CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2001-US669 A 20010130
 PRIORITY INFO.: US 2000-60/180,312 20000204
 US 2000-60/207,456 20000526
 US 2000-09/608,408 20000630
 US 2000-09/632,366 20000803
 US 2000-60/234,687 20000921
 US 2000-60/236,359 20000927
 GB 2000-0024263.6 20001004

ABEN A single exon nucleic acid microarray comprising a plurality of single
 exon nucleic acid probes for measuring gene expression in a sample
 derived from human Fetal liver is described. Also described are single
 exon nucleic acid probes expressed in the Fetal liver and their use in
 methods for detecting gene expression.
 ABFR Puce a acide nucleique (microarray) a un seul exon comportant une
 pluralite de sondes d'acide nucleique a un seul exon destinees a mesurer
 l'expression genique dans un echantillon derive de foie foetal humain.
 La presente invention concerne egalement des sondes d'acide nucleique a
 un seul exon exprimees dans le foie foetal humain et leur utilisation
 dans des methodes de detection de l'expression genique.

L20 ANSWER 17 OF 19 PCTFULL COPYRIGHT 2004 Univentio on STN
 ACCESSION NUMBER: 2001057273 PCTFULL ED 20020827
 TITLE (ENGLISH): HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES
 USEFUL FOR ANALYSIS OF GENE EXPRESSION IN HUMAN ADULT
 LIVER.
 TITLE (FRENCH): SONDAS D'ACIDE NUCLEIQUE A UN SEUL EXON DERIVEES DU
 GENOME HUMAIN UTILES POUR ANALYSER L'EXPRESSION GENIQUE
 DANS LE FOIE ADULTE HUMAIN

INVENTOR(S): PENN, Sharron, G.;
 HANZEL, David, K.;
 CHEN, Wensheng;
 RANK, David, R.

PATENT ASSIGNEE(S): AEOMICA, INC.;
 PENN, Sharron, G.;
 HANZEL, David, K.;
 CHEN, Wensheng;
 RANK, David, R.

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2001057273	A2	20010809

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU
 CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN
 IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK
 MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM
 TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD
 SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY
 DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF
 CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2001-US664 A 20010130

PRIORITY INFO.: US 2000-60/180,312 20000204
 US 2000-60/207,456 20000526
 US 2000-09/608,408 20000630
 US 2000-09/632,366 20000803
 US 2000-60/234,687 20000921
 US 2000-60/236,359 20000927
 GB 2000-0024263.6 20001004

ABEN A single exon nucleic acid microarray comprising a plurality of single exon nucleic acid probes for measuring gene expression in a sample derived from human adult liver is described. Also described are single exon nucleic acid probes expressed in the adult liver and their use in methods for detecting gene expression.

ABFR Puce a acide nucleique (microarray) a un seul exon comportant une pluralite de sondes d'acide nucleique a un seul exon destinees a mesurer l'expression genique dans un echantillon derive de foie adulte humain. La presente invention concerne egalement des sondes d'acide nucleique a un seul exon exprimees dans le foie adulte et leur utilisation dans des methodes de detection de l'expression genique.

L20 ANSWER 18 OF 19 PCTFULL COPYRIGHT 2004 Univentio on STN

ACCESSION NUMBER: 2001057272 PCTFULL ED 20020827

TITLE (ENGLISH): HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES
 USEFUL FOR ANALYSIS OF GENE EXPRESSION IN HUMAN
 PLACENTA

TITLE (FRENCH): SONDES D'ACIDE NUCLEIQUE A UN SEUL EXON DERIVEES DU
 GENOME HUMAIN UTILES POUR ANALYSER L'EXPRESSION GENIQUE
 DANS LE PLACENTA HUMAIN

INVENTOR(S): PENN, Sharron, G.;
 HANZEL, David, K.;
 CHEN, Wensheng;
 RANK, David, R.

PATENT ASSIGNEE(S): MOLECULAR DYNAMICS, INC.;
 PENN, Sharron, G.;
 HANZEL, David, K.;
 CHEN, Wensheng;
 RANK, David, R.

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2001057272	A2	20010809

DESIGNATED STATES

W:

AE	AG	AL	AM	AT	AU	AZ	BA	BB	BG	BR	BY	BZ	CA	CH	CN	CR	CU
CZ	DE	DK	DM	DZ	EE	ES	FI	GB	GD	GE	GH	GM	HR	HU	ID	IL	IN
IS	JP	KE	KG	KP	KR	KZ	LC	LK	LR	LS	LT	LU	LV	MA	MD	MG	MK
MN	MW	MX	MZ	NO	NZ	PL	PT	RO	RU	SD	SE	SG	SI	SK	SL	TJ	TM
TR	TT	TZ	UA	UG	US	UZ	VN	YU	ZA	ZW	GH	GM	KE	LS	MW	MZ	SD
SL	SZ	TZ	UG	ZW	AM	AZ	BY	KG	KZ	MD	RU	TJ	TM	AT	BE	CH	CY
DE	DK	ES	FI	FR	GB	GR	IE	IT	LU	MC	NL	PT	SE	TR	BF	BJ	CF
CG	CI	CM	GA	GN	GW	ML	MR	NE	SN	TD	TG						

APPLICATION INFO.:

WO 2001-US663 A 20010130

PRIORITY INFO.:

US 2000-60/180,312 20000204

US 2000-60/207,456 20000526

US 2000-09/608,408 20000630

US 2000-09/632,366 20000803

US 2000-60/234,687 20000921

US 2000-60/236,359 20000927

GB 2000-0024263.6 20001004

ABEN A single exon nucleic acid microarray comprising a plurality of single exon nucleic acid probes for measuring gene expression in a sample derived from human placenta is described. Also described are single exon nucleic acid probes expressed in the placenta and their use in methods for detecting gene expression.

ABFR Puce a acide nucleique (microarray) a un seul exon comportant une pluralite de sondes d'acide nucleique a un seul exon destinees a mesurer l'expression genique dans un echantillon derive de placenta humain. La presente invention concerne egalement des sondes d'acide nucleique a un seul exon exprimees dans le placenta et leur utilisation dans des methodes de detection de l'expression genique.

L20 ANSWER 19 OF 19 PCTFULL COPYRIGHT 2004 Univentio on STN

ACCESSION NUMBER: 2001057182 PCTFULL ED 20020827

TITLE (ENGLISH): NUCLEIC ACIDS, PROTEINS, AND ANTIBODIES

TITLE (FRENCH): ACIDES NUCLEIQUES, PROTEINES ET ANTICORPS

INVENTOR(S): ROSEN, Craig, A.;

BARASH, Steven, C.;

RUBEN, Steven, M.

PATENT ASSIGNEE(S): HUMAN GENOME SCIENCES, INC.;

ROSEN, Craig, A.;

BARASH, Steven, C.;

RUBEN, Steven, M.

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2001057182	A2	20010809

DESIGNATED STATES

W:

AE	AG	AL	AM	AT	AU	AZ	BA	BB	BG	BR	BY	BZ	CA	CH	CN	CR	CU
CZ	DE	DK	DM	DZ	EE	ES	FI	GB	GD	GE	GH	GM	HR	HU	ID	IL	IN
IS	JP	KE	KG	KP	KR	KZ	LC	LK	LR	LS	LT	LU	LV	MA	MD	MG	MK
MN	MW	MX	MZ	NO	NZ	PL	PT	RO	RU	SD	SE	SG	SI	SK	SL	TJ	TM
TR	TT	TZ	UA	UG	US	UZ	VN	YU	ZA	ZW	GH	GM	KE	LS	MW	MZ	SD
SL	SZ	TZ	UG	ZW	AM	AZ	BY	KG	KZ	MD	RU	TJ	TM	AT	BE	CH	CY
DE	DK	ES	FI	FR	GB	GR	IE	IT	LU	MC	NL	PT	SE	TR	BF	BJ	CF
CG	CI	CM	GA	GN	GW	ML	MR	NE	SN	TD	TG						

APPLICATION INFO.:

WO 2001-US1354 A 20010117

PRIORITY INFO.:

US 2000-60/179,065	20000131
US 2000-60/180,628	20000204
US 2000-60/184,664	20000224
US 2000-60/186,350	20000302
US 2000-60/189,874	20000316
US 2000-60/190,076	20000317
US 2000-60/198,123	20000418
US 2000-60/205,515	20000519
US 2000-60/209,467	20000607
US 2000-60/214,886	20000628
US 2000-60/215,135	20000630
US 2000-60/216,647	20000707
US 2000-60/216,880	20000707
US 2000-60/217,487	20000711
US 2000-60/217,496	20000711
US 2000-60/218,290	20000714
US 2000-60/220,963	20000726
US 2000-60/220,964	20000726
US 2000-60/225,757	20000814
US 2000-60/225,270	20000814
US 2000-60/225,447	20000814
US 2000-60/225,266	20000814
US 2000-60/225,213	20000814
US 2000-60/225,759	20000814
US 2000-60/224,519	20000814
US 2000-60/224,518	20000814
US 2000-60/225,268	20000814
US 2000-60/225,758	20000814
US 2000-60/225,267	20000814
US 2000-60/225,214	20000814
US 2000-60/226,279	20000818
US 2000-60/226,868	20000822
US 2000-60/227,182	20000822
US 2000-60/226,681	20000822
US 2000-60/227,009	20000823
US 2000-60/228,924	20000830
US 2000-60/229,344	20000901
US 2000-60/229,343	20000901
US 2000-60/229,287	20000901
US 2000-60/229,345	20000901
US 2000-60/229,513	20000905
US 2000-60/229,509	20000905
US 2000-60/230,438	20000906
US 2000-60/230,437	20000906
US 2000-60/231,413	20000908
US 2000-60/232,080	20000908
US 2000-60/231,414	20000908
US 2000-60/231,244	20000908
US 2000-60/232,081	20000908
US 2000-60/231,242	20000908
US 2000-60/231,243	20000908
US 2000-60/231,968	20000912
US 2000-60/232,401	20000914
US 2000-60/232,399	20000914
US 2000-60/232,400	20000914
US 2000-60/232,397	20000914
US 2000-60/233,063	20000914
US 2000-60/233,064	20000914
US 2000-60/233,065	20000914
US 2000-60/232,398	20000914

US 2000-60/234,223	20000921
US 2000-60/234,274	20000921
US 2000-60/234,997	20000925
US 2000-60/234,998	20000925
US 2000-60/235,484	20000926
US 2000-60/235,834	20000927
US 2000-60/235,836	20000927
US 2000-60/236,369	20000929
US 2000-60/236,327	20000929
US 2000-60/236,370	20000929
US 2000-60/236,368	20000929
US 2000-60/236,367	20000929
US 2000-60/237,039	20001002
US 2000-60/237,038	20001002
US 2000-60/237,040	20001002
US 2000-60/237,037	20001002
US 2000-60/236,802	20001002
US 2000-60/239,937	20001013
US 2000-60/239,935	20001013
US 2000-60/241,785	20001020
US 2000-60/241,809	20001020
US 2000-60/240,960	20001020
US 2000-60/241,787	20001020
US 2000-60/241,808	20001020
US 2000-60/241,221	20001020
US 2000-60/241,786	20001020
US 2000-60/241,826	20001020
US 2000-60/244,617	20001101
US 2000-60/246,474	20001108
US 2000-60/246,532	20001108
US 2000-60/246,476	20001108
US 2000-60/246,526	20001108
US 2000-60/246,475	20001108
US 2000-60/246,525	20001108
US 2000-60/246,528	20001108
US 2000-60/246,527	20001108
US 2000-60/246,477	20001108
US 2000-60/246,611	20001108
US 2000-60/246,610	20001108
US 2000-60/246,613	20001108
US 2000-60/246,609	20001108
US 2000-60/246,478	20001108
US 2000-60/246,524	20001108
US 2000-60/246,523	20001108
US 2000-60/249,299	20001117
US 2000-60/249,210	20001117
US 2000-60/249,216	20001117
US 2000-60/249,217	20001117
US 2000-60/249,211	20001117
US 2000-60/249,215	20001117
US 2000-60/249,218	20001117
US 2000-60/249,208	20001117
US 2000-60/249,213	20001117
US 2000-60/249,212	20001117
US 2000-60/249,207	20001117
US 2000-60/249,245	20001117
US 2000-60/249,244	20001117
US 2000-60/249,297	20001117
US 2000-60/249,214	20001117
US 2000-60/249,264	20001117

US 2000-60/249,209	20001117
US 2000-60/249,300	20001117
US 2000-60/249,265	20001117
US 2000-60/250,391	20001201
US 2000-60/250,160	20001201
US 2000-60/256,719	20001205
US 2000-60/251,030	20001205
US 2000-60/251,988	20001205
US 2000-60/251,479	20001206
US 2000-60/251,869	20001208
US 2000-60/251,856	20001208
US 2000-60/251,868	20001208
US 2000-60/251,990	20001208
US 2000-60/251,989	20001208
US 2000-60/254,097	20001211
US 2001-60/259,678	20010105

ABEN The present invention relates to novel immune/hematopoietic-related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "immune/hematopoietic antigens", and the use of such immune/hematopoietic antigens for detecting immune/hematopoietic-related diseases and/or disorders, particularly the presence of cancer and cancer metastases of cells of hematopoietic origin. More specifically, isolated immune/hematopoietic associated nucleic acid molecules are provided encoding novel immune/hematopoietic associated polypeptides. Novel immune/hematopoietic polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human immune/hematopoietic associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the immune system or cells and tissues associated with hematopoiesis, including cancers of cells of hematopoietic origin, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

ABFR La presente invention concerne de nouveaux polynucleotides a association immunitaire/hematopoietique et les polypeptides codes par ces polynucleotides, ici collectivement designes comme £ antigenes immunitaires/hematopoietiques , ainsi que l'utilisation de ces antigenes immunitaires/hematopoietiques dans la detection de maladies et/ou troubles a association immunitaire/hematopoietique, notamment la presence de cancer et de metastases cancéreuses de cellules d'origine hematopoietique. Cette invention concerne plus specifiquement des molecules d'acide nucleique a association immunitaire/hematopoietique isolees, qui codent les nouveaux polypeptides a association immunitaire/hematopoietique. La presente invention concerne egalement de nouveaux polypeptides et anticorps immunitaires/hematopoietiques qui se lient a ces polypeptides. La presente invention concerne egalement des vecteurs, des cellules hotes, ainsi que des procedes de recombinaison et de synthese permettant de produire des polynucleotides et/ou polypeptides a association immunitaire/hematopoietique humains. La presente invention concerne egalement des procedes diagnostiques et therapeutiques permettant de diagnostiquer, de traiter, de prevenir et/ou de pronostiquer des troubles associes au systeme ou aux cellules immunitaires et des tissus associes a l'hematopoiese, comprenant des cancers de cellules d'origine hematopoietique, ainsi que des procedes therapeutiques permettant de traiter de tels troubles. La presente

invention concerne également des procedes de criblage permettant d'identifier des agonistes et des antagonistes des polynucleotides et polypeptides selon cette invention. En outre, cette invention concerne des procedes et/ou des compositions permettant d'inhiber la production et le fonctionnement des polypeptides selon cette invention.